Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate
NCT ID: NCT00262600
Last Updated: 2019-04-17
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
18113 participants
INTERVENTIONAL
2005-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial
NCT00808067
Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation
NCT01606995
Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism
NCT00291330
Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)
NCT02164864
Replication of the RELY Anticoagulant Trial in Healthcare Claims Data
NCT04593043
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dabigatran dose 2
twice a day
Dabigatran dose 2
twice a day
Warfarin
once a day
warfarin
once a day
Dabigatran dose 1
twice a day
Dabigatran dose 1
twice daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
warfarin
once a day
Dabigatran dose 1
twice daily
Dabigatran dose 2
twice a day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
2. Severe, disabling stroke within the previous 6 months, or any stroke within the previous 14 days
3. Conditions associated with an increased risk of bleeding
4. Contraindication to warfarin treatment
5. Reversible causes of atrial fibrillation (e.g., cardiac surgery, pulmonary embolism, untreated hyperthyroidism).
6. Plan to perform a pulmonary vein ablation or surgery for cure of the AF
7. Severe renal impairment (estimated creatinine clearance \<=30 mL/min)
8. Active infective endocarditis
9. Active liver disease
10. Women who are pregnant, lactating, or of childbearing potential who refuse to use a medically acceptable form of contraception throughout the study
11. Anaemia (haemoglobin \<100g/L) or thrombocytopenia (platelet count \<100 x 109/L)
12. Patients who have developed transaminase elevations upon exposure to ximelagatran
13. Patients who have received an investigational drug in the past 30 days or are participating in another drug study
14. Patients considered unreliable by the investigator concerning the requirements for follow-up during the study and/or compliance with study drug administration, has a life expectancy less than the expected duration of the trial due to concomitant disease, or has any condition which in the opinion of the investigator, would not allow safe participation in the study (e.g., drug addiction, alcohol abuse)
15. Any known hypersensitivity to galactose if the warfarin used contains galactose.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Population Health Research Institute
OTHER
Uppsala University
OTHER
Boehringer Ingelheim
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Boehringer Ingelheim
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Boehringer Ingelheim
Role: STUDY_CHAIR
Boehringer Ingelheim
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
1160.26.0009 Boehringer Ingelheim Investigational Site
Birmingham, Alabama, United States
1160.26.0046 Boehringer Ingelheim Investigational Site
Birmingham, Alabama, United States
1160.26.0057 Boehringer Ingelheim Investigational Site
Birmingham, Alabama, United States
1160.26.0211 Boehringer Ingelheim Investigational Site
Birmingham, Alabama, United States
1160.26.0206 Boehringer Ingelheim Investigational Site
Huntsville, Alabama, United States
1160.26.0115 Boehringer Ingelheim Investigational Site
Mobile, Alabama, United States
1160.26.0104 Boehringer Ingelheim Investigational Site
Lake Havasu City, Arizona, United States
1160.26.0304 Boehringer Ingelheim Investigational Site
Peoria, Arizona, United States
1160.26.0185 Boehringer Ingelheim Investigational Site
Tucson, Arizona, United States
1160.26.0305 Boehringer Ingelheim Investigational Site
Tucson, Arizona, United States
1160.26.0038 Boehringer Ingelheim Investigational Site
Hot Springs, Arkansas, United States
1160.26.0302 Boehringer Ingelheim Investigational Site
Jonesboro, Arkansas, United States
1160.26.0121 Boehringer Ingelheim Investigational Site
Little Rock, Arkansas, United States
1160.26.0191 Boehringer Ingelheim Investigational Site
Little Rock, Arkansas, United States
1160.26.0204 Boehringer Ingelheim Investigational Site
Little Rock, Arkansas, United States
1160.26.0213 Boehringer Ingelheim Investigational Site
Little Rock, Arkansas, United States
1160.26.0455 Boehringer Ingelheim Investigational Site
Little Rock, Arkansas, United States
1160.26.0388 Boehringer Ingelheim Investigational Site
Anaheim, California, United States
1160.26.0441 Boehringer Ingelheim Investigational Site
Carmichael, California, United States
1160.26.0145 Boehringer Ingelheim Investigational Site
French Camp, California, United States
1160.26.0333 Boehringer Ingelheim Investigational Site
Fullerton, California, United States
1160.26.0384 Boehringer Ingelheim Investigational Site
La Jolla, California, United States
1160.26.0091 Boehringer Ingelheim Investigational Site
La Mesa, California, United States
1160.26.0246 Boehringer Ingelheim Investigational Site
Lancaster, California, United States
1160.26.0345 Boehringer Ingelheim Investigational Site
Larkspur, California, United States
1160.26.0217 Boehringer Ingelheim Investigational Site
Loma Linda, California, United States
1160.26.0059 Boehringer Ingelheim Investigational Site
Los Angeles, California, United States
1160.26.0088 Boehringer Ingelheim Investigational Site
Los Angeles, California, United States
1160.26.0337 Boehringer Ingelheim Investigational Site
Los Angeles, California, United States
1160.26.0326 Boehringer Ingelheim Investigational Site
Mather, California, United States
1160.26.0070 Boehringer Ingelheim Investigational Site
Merced, California, United States
1160.26.0349 Boehringer Ingelheim Investigational Site
Oakland, California, United States
1160.26.0016 Boehringer Ingelheim Investigational Site
Oceanside, California, United States
1160.26.0087 Boehringer Ingelheim Investigational Site
Palm Springs, California, United States
1160.26.0459 Boehringer Ingelheim Investigational Site
Pasadena, California, United States
1160.26.0216 Boehringer Ingelheim Investigational Site
Redondo Beach, California, United States
1160.26.0135 Boehringer Ingelheim Investigational Site
Riverside, California, United States
1160.26.0162 Boehringer Ingelheim Investigational Site
Sacramento, California, United States
1160.26.0300 Boehringer Ingelheim Investigational Site
Sacramento, California, United States
1160.26.0371 Boehringer Ingelheim Investigational Site
Sacramento, California, United States
1160.26.0116 Boehringer Ingelheim Investigational Site
San Diego, California, United States
1160.26.0148 Boehringer Ingelheim Investigational Site
San Diego, California, United States
1160.26.0270 Boehringer Ingelheim Investigational Site
San Diego, California, United States
1160.26.0284 Boehringer Ingelheim Investigational Site
San Diego, California, United States
1160.26.0351 Boehringer Ingelheim Investigational Site
Santa Ana, California, United States
1160.26.0043 Boehringer Ingelheim Investigational Site
Santa Rosa, California, United States
1160.26.0462 Boehringer Ingelheim Investigational Site
Sylmar, California, United States
1160.26.0276 Boehringer Ingelheim Investigational Site
Torrance, California, United States
1160.26.0379 Boehringer Ingelheim Investigational Site
Walnut Creek, California, United States
1160.26.0419 Boehringer Ingelheim Investigational Site
Aurora, Colorado, United States
1160.26.0321 Boehringer Ingelheim Investigational Site
Colorado Springs, Colorado, United States
1160.26.0449 Boehringer Ingelheim Investigational Site
Colorado Springs, Colorado, United States
1160.26.0360 Boehringer Ingelheim Investigational Site
Denver, Colorado, United States
1160.26.0413 Boehringer Ingelheim Investigational Site
Denver, Colorado, United States
1160.26.0362 Boehringer Ingelheim Investigational Site
Fort Collins, Colorado, United States
1160.26.0399 Boehringer Ingelheim Investigational Site
Greeley, Colorado, United States
1160.26.0058 Boehringer Ingelheim Investigational Site
Bridgeport, Connecticut, United States
1160.26.0241 Boehringer Ingelheim Investigational Site
Bridgeport, Connecticut, United States
1160.26.0278 Boehringer Ingelheim Investigational Site
Bridgeport, Connecticut, United States
1160.26.0085 Boehringer Ingelheim Investigational Site
Fairfield, Connecticut, United States
1160.26.0482 Boehringer Ingelheim Investigational Site
Guilford, Connecticut, United States
1160.26.0366 Boehringer Ingelheim Investigational Site
Newark, Delaware, United States
1160.26.0343 Boehringer Ingelheim Investigational Site
Washington D.C., District of Columbia, United States
1160.26.0022 Boehringer Ingelheim Investigational Site
Atlantis, Florida, United States
1160.26.0382 Boehringer Ingelheim Investigational Site
Boynton Beach, Florida, United States
1160.26.0056 Boehringer Ingelheim Investigational Site
Brandon, Florida, United States
1160.26.0105 Boehringer Ingelheim Investigational Site
Clearwater, Florida, United States
1160.26.0296 Boehringer Ingelheim Investigational Site
Clearwater, Florida, United States
1160.26.0429 Boehringer Ingelheim Investigational Site
Clearwater, Florida, United States
1160.26.0376 Boehringer Ingelheim Investigational Site
Daytona Beach, Florida, United States
1160.26.0411 Boehringer Ingelheim Investigational Site
Deerfield Beach, Florida, United States
1160.26.0074 Boehringer Ingelheim Investigational Site
Fort Myers, Florida, United States
1160.26.0239 Boehringer Ingelheim Investigational Site
Gainesville, Florida, United States
1160.26.0260 Boehringer Ingelheim Investigational Site
Hollywood, Florida, United States
1160.26.0265 Boehringer Ingelheim Investigational Site
Hollywood, Florida, United States
1160.26.0100 Boehringer Ingelheim Investigational Site
Inverness, Florida, United States
1160.26.0033 Boehringer Ingelheim Investigational Site
Jacksonville, Florida, United States
1160.26.0089 Boehringer Ingelheim Investigational Site
Jacksonville, Florida, United States
1160.26.0232 Boehringer Ingelheim Investigational Site
Jacksonville, Florida, United States
1160.26.0240 Boehringer Ingelheim Investigational Site
Jacksonville, Florida, United States
1160.26.0427 Boehringer Ingelheim Investigational Site
Jacksonville, Florida, United States
1160.26.0464 Boehringer Ingelheim Investigational Site
Jacksonville, Florida, United States
1160.26.0209 Boehringer Ingelheim Investigational Site
Jacksonville Beach, Florida, United States
1160.26.0012 Boehringer Ingelheim Investigational Site
Lakeland, Florida, United States
1160.26.0259 Boehringer Ingelheim Investigational Site
Melbourne, Florida, United States
1160.26.0358 Boehringer Ingelheim Investigational Site
Melbourne, Florida, United States
1160.26.0034 Boehringer Ingelheim Investigational Site
Miami, Florida, United States
1160.26.0199 Boehringer Ingelheim Investigational Site
Miami, Florida, United States
1160.26.0227 Boehringer Ingelheim Investigational Site
Orlando, Florida, United States
1160.26.0095 Boehringer Ingelheim Investigational Site
Ormond Beach, Florida, United States
1160.26.0037 Boehringer Ingelheim Investigational Site
Pensacola, Florida, United States
1160.26.0076 Boehringer Ingelheim Investigational Site
Pensacola, Florida, United States
1160.26.0081 Boehringer Ingelheim Investigational Site
Pensacola, Florida, United States
1160.26.0111 Boehringer Ingelheim Investigational Site
Pensacola, Florida, United States
1160.26.0137 Boehringer Ingelheim Investigational Site
Port Charlotte, Florida, United States
1160.26.0389 Boehringer Ingelheim Investigational Site
Port Charlotte, Florida, United States
1160.26.0417 Boehringer Ingelheim Investigational Site
Port Charlotte, Florida, United States
1160.26.0332 Boehringer Ingelheim Investigational Site
Rockledge, Florida, United States
1160.26.0226 Boehringer Ingelheim Investigational Site
Safety Harbor, Florida, United States
1160.26.0031 Boehringer Ingelheim Investigational Site
Sarasota, Florida, United States
1160.26.0385 Boehringer Ingelheim Investigational Site
Sarasota, Florida, United States
1160.26.0015 Boehringer Ingelheim Investigational Site
St. Petersburg, Florida, United States
1160.26.0339 Boehringer Ingelheim Investigational Site
St. Petersburg, Florida, United States
1160.26.0010 Boehringer Ingelheim Investigational Site
Stuart, Florida, United States
1160.26.0327 Boehringer Ingelheim Investigational Site
Tamarac, Florida, United States
1160.26.0271 Boehringer Ingelheim Investigational Site
Tampa, Florida, United States
1160.26.0328 Boehringer Ingelheim Investigational Site
Tampa, Florida, United States
1160.26.0381 Boehringer Ingelheim Investigational Site
Tampa, Florida, United States
1160.26.0019 Boehringer Ingelheim Investigational Site
Vero Beach, Florida, United States
1160.26.0159 Boehringer Ingelheim Investigational Site
Atlanta, Georgia, United States
1160.26.0283 Boehringer Ingelheim Investigational Site
Atlanta, Georgia, United States
1160.26.0338 Boehringer Ingelheim Investigational Site
Atlanta, Georgia, United States
1160.26.0021 Boehringer Ingelheim Investigational Site
Augusta, Georgia, United States
1160.26.0319 Boehringer Ingelheim Investigational Site
Augusta, Georgia, United States
1160.26.0092 Boehringer Ingelheim Investigational Site
Blue Ridge, Georgia, United States
1160.26.0161 Boehringer Ingelheim Investigational Site
Conyers, Georgia, United States
1160.26.0026 Boehringer Ingelheim Investigational Site
Coeur d'Alene, Idaho, United States
1160.26.0218 Boehringer Ingelheim Investigational Site
Berwyn, Illinois, United States
1160.26.0184 Boehringer Ingelheim Investigational Site
Chicago, Illinois, United States
1160.26.0233 Boehringer Ingelheim Investigational Site
Chicago, Illinois, United States
1160.26.0324 Boehringer Ingelheim Investigational Site
Chicago, Illinois, United States
1160.26.0457 Boehringer Ingelheim Investigational Site
Chicago, Illinois, United States
1160.26.0237 Boehringer Ingelheim Investigational Site
Evanston, Illinois, United States
1160.26.0236 Boehringer Ingelheim Investigational Site
Glenview, Illinois, United States
1160.26.0396 Boehringer Ingelheim Investigational Site
Hines, Illinois, United States
1160.26.0438 Boehringer Ingelheim Investigational Site
Maywood, Illinois, United States
1160.26.0331 Boehringer Ingelheim Investigational Site
Melrose Park, Illinois, United States
1160.26.0364 Boehringer Ingelheim Investigational Site
Normal, Illinois, United States
1160.26.0109 Boehringer Ingelheim Investigational Site
North Chicago, Illinois, United States
1160.26.0152 Boehringer Ingelheim Investigational Site
Oak Lawn, Illinois, United States
1160.26.0198 Boehringer Ingelheim Investigational Site
Rockford, Illinois, United States
1160.26.0433 Boehringer Ingelheim Investigational Site
Winfield, Illinois, United States
1160.26.0041 Boehringer Ingelheim Investigational Site
Evansville, Indiana, United States
1160.26.0377 Boehringer Ingelheim Investigational Site
Fort Wayne, Indiana, United States
1160.26.0288 Boehringer Ingelheim Investigational Site
Indianapolis, Indiana, United States
1160.26.0352 Boehringer Ingelheim Investigational Site
Indianapolis, Indiana, United States
1160.26.0436 Boehringer Ingelheim Investigational Site
Indianapolis, Indiana, United States
1160.26.0028 Boehringer Ingelheim Investigational Site
Jeffersonville, Indiana, United States
1160.26.0235 Boehringer Ingelheim Investigational Site
South Bend, Indiana, United States
1160.26.0268 Boehringer Ingelheim Investigational Site
Dubuque, Iowa, United States
1160.26.0001 Boehringer Ingelheim Investigational Site
West Des Moines, Iowa, United States
1160.26.0189 Boehringer Ingelheim Investigational Site
West Des Moines, Iowa, United States
1160.26.0357 Boehringer Ingelheim Investigational Site
West Des Moines, Iowa, United States
1160.26.0354 Boehringer Ingelheim Investigational Site
Wichita, Kansas, United States
1160.26.0077 Boehringer Ingelheim Investigational Site
Bowling Green, Kentucky, United States
1160.26.0138 Boehringer Ingelheim Investigational Site
Crestview Hills, Kentucky, United States
1160.26.0422 Boehringer Ingelheim Investigational Site
Lexington, Kentucky, United States
1160.26.0178 Boehringer Ingelheim Investigational Site
Louisville, Kentucky, United States
1160.26.0397 Boehringer Ingelheim Investigational Site
Louisville, Kentucky, United States
1160.26.0310 Boehringer Ingelheim Investigational Site
Owensboro, Kentucky, United States
1160.26.0011 Boehringer Ingelheim Investigational Site
Baton Rouge, Louisiana, United States
1160.26.0144 Boehringer Ingelheim Investigational Site
Baton Rouge, Louisiana, United States
1160.26.0404 Boehringer Ingelheim Investigational Site
Baton Rouge, Louisiana, United States
1160.26.0093 Boehringer Ingelheim Investigational Site
Covington, Louisiana, United States
1160.26.0340 Boehringer Ingelheim Investigational Site
Lacombe, Louisiana, United States
1160.26.0018 Boehringer Ingelheim Investigational Site
Lafayette, Louisiana, United States
1160.26.0391 Boehringer Ingelheim Investigational Site
Lafayette, Louisiana, United States
1160.26.0252 Boehringer Ingelheim Investigational Site
Morgan City, Louisiana, United States
1160.26.0132 Boehringer Ingelheim Investigational Site
New Iberia, Louisiana, United States
1160.26.0299 Tulane University School Of Medicine
New Orleans, Louisiana, United States
1160.26.0048 Boehringer Ingelheim Investigational Site
Shreveport, Louisiana, United States
1160.26.0096 Boehringer Ingelheim Investigational Site
Auburn, Maine, United States
1160.26.0068 Boehringer Ingelheim Investigational Site
Scarborough, Maine, United States
1160.26.0114 Boehringer Ingelheim Investigational Site
Annapolis, Maryland, United States
1160.26.0164 Boehringer Ingelheim Investigational Site
Annapolis, Maryland, United States
1160.26.0023 Boehringer Ingelheim Investigational Site
Baltimore, Maryland, United States
1160.26.0047 Boehringer Ingelheim Investigational Site
Baltimore, Maryland, United States
1160.26.0079 Boehringer Ingelheim Investigational Site
Baltimore, Maryland, United States
1160.26.0186 Boehringer Ingelheim Investigational Site
Baltimore, Maryland, United States
1160.26.0194 Boehringer Ingelheim Investigational Site
Baltimore, Maryland, United States
1160.26.0255 Boehringer Ingelheim Investigational Site
Bel Air, Maryland, United States
1160.26.0398 Boehringer Ingelheim Investigational Site
Columbia, Maryland, United States
1160.26.0177 Boehringer Ingelheim Investigational Site
Rockville, Maryland, United States
1160.26.0073 Boehringer Ingelheim Investigational Site
Salisbury, Maryland, United States
1160.26.0207 Boehringer Ingelheim Investigational Site
Salisbury, Maryland, United States
1160.26.0196 Boehringer Ingelheim Investigational Site
Takoma Park, Maryland, United States
1160.26.0187 Boehringer Ingelheim Investigational Site
Towson, Maryland, United States
1160.26.0052 Boehringer Ingelheim Investigational Site
Westminster, Maryland, United States
1160.26.0042 Boehringer Ingelheim Investigational Site
Ayer, Massachusetts, United States
1160.26.0401 Boehringer Ingelheim Investigational Site
Boston, Massachusetts, United States
1160.26.0160 Boehringer Ingelheim Investigational Site
East Bridgewater, Massachusetts, United States
1160.26.0443 Boehringer Ingelheim Investigational Site
Haverhill, Massachusetts, United States
1160.26.0452 Boehringer Ingelheim Investigational Site
Haverhill, Massachusetts, United States
1160.26.0029 Boehringer Ingelheim Investigational Site
Natick, Massachusetts, United States
1160.26.0446 Boehringer Ingelheim Investigational Site
Newtown, Massachusetts, United States
1160.26.0003 Boehringer Ingelheim Investigational Site
North Dartmouth, Massachusetts, United States
1160.26.0470 Boehringer Ingelheim Investigational Site
Northborough, Massachusetts, United States
1160.26.0308 Boehringer Ingelheim Investigational Site
Worcester, Massachusetts, United States
1160.26.0141 Boehringer Ingelheim Investigational Site
Bloomfield Hills, Michigan, United States
1160.26.0225 Boehringer Ingelheim Investigational Site
Detroit, Michigan, United States
1160.26.0154 Boehringer Ingelheim Investigational Site
Grand Blanc, Michigan, United States
1160.26.0030 Boehringer Ingelheim Investigational Site
Grand Rapids, Michigan, United States
1160.26.0171 Boehringer Ingelheim Investigational Site
Kalamazoo, Michigan, United States
1160.26.0205 Boehringer Ingelheim Investigational Site
Lapeer, Michigan, United States
1160.26.0279 Boehringer Ingelheim Investigational Site
Muskegon, Michigan, United States
1160.26.0445 Boehringer Ingelheim Investigational Site
Petoskey, Michigan, United States
1160.26.0274 Boehringer Ingelheim Investigational Site
Rochester Hills, Michigan, United States
1160.26.0165 Boehringer Ingelheim Investigational Site
Saginaw, Michigan, United States
1160.26.0020 Boehringer Ingelheim Investigational Site
Troy, Michigan, United States
1160.26.0188 Boehringer Ingelheim Investigational Site
Ypsilanti, Michigan, United States
1160.26.0131 Boehringer Ingelheim Investigational Site
Minneapolis, Minnesota, United States
1160.26.0421 Boehringer Ingelheim Investigational Site
Minneapolis, Minnesota, United States
1160.26.0202 Boehringer Ingelheim Investigational Site
Robbinsdale, Minnesota, United States
1160.26.0101 Boehringer Ingelheim Investigational Site
Saint Paul, Minnesota, United States
1160.26.0086 Boehringer Ingelheim Investigational Site
Gulfport, Mississippi, United States
1160.26.0119 Boehringer Ingelheim Investigational Site
Tupelo, Mississippi, United States
1160.26.0055 Boehringer Ingelheim Investigational Site
Columbia, Missouri, United States
1160.26.0172 Boehringer Ingelheim Investigational Site
Columbia, Missouri, United States
1160.26.0257 Boehringer Ingelheim Investigational Site
Kansas City, Missouri, United States
1160.26.0266 Boehringer Ingelheim Investigational Site
Kansas City, Missouri, United States
1160.26.0336 Boehringer Ingelheim Investigational Site
Saint Charles, Missouri, United States
1160.26.0249 Boehringer Ingelheim Investigational Site
St Louis, Missouri, United States
1160.26.0027 Boehringer Ingelheim Investigational Site
Kalispell, Montana, United States
1160.26.0128 Boehringer Ingelheim Investigational Site
Alliance, Nebraska, United States
1160.26.0110 Boehringer Ingelheim Investigational Site
Omaha, Nebraska, United States
1160.26.0355 Boehringer Ingelheim Investigational Site
Papillion, Nebraska, United States
1160.26.0346 Boehringer Ingelheim Investigational Site
Henderson, Nevada, United States
1160.26.0066 Boehringer Ingelheim Investigational Site
Las Vegas, Nevada, United States
1160.26.0174 Boehringer Ingelheim Investigational Site
Las Vegas, Nevada, United States
1160.26.0430 Boehringer Ingelheim Investigational Site
Las Vegas, Nevada, United States
1160.26.0190 Boehringer Ingelheim Investigational Site
Lebanon, New Hampshire, United States
1160.26.0142 Boehringer Ingelheim Investigational Site
Browns Mills, New Jersey, United States
1160.26.0125 Boehringer Ingelheim Investigational Site
Cherry Hill, New Jersey, United States
1160.26.0432 Boehringer Ingelheim Investigational Site
Elmer, New Jersey, United States
1160.26.0448 Boehringer Ingelheim Investigational Site
Englewood, New Jersey, United States
1160.26.0248 Boehringer Ingelheim Investigational Site
Flemington, New Jersey, United States
1160.26.0244 Boehringer Ingelheim Investigational Site
Haddon Heights, New Jersey, United States
1160.26.0243 Boehringer Ingelheim Investigational Site
New Brunswick, New Jersey, United States
1160.26.0478 Boehringer Ingelheim Investigational Site
Oakland, New Jersey, United States
1160.26.0392 Boehringer Ingelheim Investigational Site
Ocean City, New Jersey, United States
1160.26.0472 Boehringer Ingelheim Investigational Site
Paterson, New Jersey, United States
1160.26.0221 Boehringer Ingelheim Investigational Site
Voorhees Township, New Jersey, United States
1160.26.0254 Boehringer Ingelheim Investigational Site
Westwood, New Jersey, United States
1160.26.0127 Boehringer Ingelheim Investigational Site
Albuquerque, New Mexico, United States
1160.26.0423 Boehringer Ingelheim Investigational Site
Albuquerque, New Mexico, United States
1160.26.0476 Boehringer Ingelheim Investigational Site
Albany, New York, United States
1160.26.0063 Boehringer Ingelheim Investigational Site
Buffalo, New York, United States
1160.26.0044 Boehringer Ingelheim Investigational Site
Cortlandt Manor, New York, United States
1160.26.0373 Boehringer Ingelheim Investigational Site
Flushing, New York, United States
1160.26.0045 Boehringer Ingelheim Investigational Site
Garden City, New York, United States
1160.26.0251 Boehringer Ingelheim Investigational Site
Kingston, New York, United States
1160.26.0229 Boehringer Ingelheim Investigational Site
Mineola, New York, United States
1160.26.0451 Boehringer Ingelheim Investigational Site
Mineola, New York, United States
1160.26.0090 Boehringer Ingelheim Investigational Site
New Hyde Park, New York, United States
1160.26.0183 Boehringer Ingelheim Investigational Site
New Rochelle, New York, United States
1160.26.0316 Boehringer Ingelheim Investigational Site
New York, New York, United States
1160.26.0146 Boehringer Ingelheim Investigational Site
North Massapequa, New York, United States
1160.26.0210 Boehringer Ingelheim Investigational Site
Northport, New York, United States
1160.26.0075 Boehringer Ingelheim Investigational Site
Poughkeepsie, New York, United States
1160.26.0197 Boehringer Ingelheim Investigational Site
Rochester, New York, United States
1160.26.0320 Boehringer Ingelheim Investigational Site
Rochester, New York, United States
1160.26.0064 Boehringer Ingelheim Investigational Site
Scarsdale, New York, United States
1160.26.0113 Boehringer Ingelheim Investigational Site
The Bronx, New York, United States
1160.26.0281 Boehringer Ingelheim Investigational Site
The Bronx, New York, United States
1160.26.0414 Boehringer Ingelheim Investigational Site
Troy, New York, United States
1160.26.0356 Boehringer Ingelheim Investigational Site
Watertown, New York, United States
1160.26.0039 Boehringer Ingelheim Investigational Site
Williamsville, New York, United States
1160.26.0353 Boehringer Ingelheim Investigational Site
Asheville, North Carolina, United States
1160.26.0080 Boehringer Ingelheim Investigational Site
Charlotte, North Carolina, United States
1160.26.0412 Boehringer Ingelheim Investigational Site
Charlotte, North Carolina, United States
1160.26.0350 Boehringer Ingelheim Investigational Site
Gastonia, North Carolina, United States
1160.26.0322 Boehringer Ingelheim Investigational Site
Greensboro, North Carolina, United States
1160.26.0173 Boehringer Ingelheim Investigational Site
High Point, North Carolina, United States
1160.26.0108 Boehringer Ingelheim Investigational Site
Lexington, North Carolina, United States
1160.26.0006 Boehringer Ingelheim Investigational Site
Pinehurst, North Carolina, United States
1160.26.0002 Boehringer Ingelheim Investigational Site
Statesville, North Carolina, United States
1160.26.0069 Boehringer Ingelheim Investigational Site
Statesville, North Carolina, United States
1160.26.0372 Boehringer Ingelheim Investigational Site
Wilmington, North Carolina, United States
1160.26.0094 Boehringer Ingelheim Investigational Site
Winston-Salem, North Carolina, United States
1160.26.0425 Boehringer Ingelheim Investigational Site
Winston-Salem, North Carolina, United States
1160.26.0102 Boehringer Ingelheim Investigational Site
Grand Forks, North Dakota, United States
1160.26.0222 Boehringer Ingelheim Investigational Site
Jamestown, North Dakota, United States
1160.26.0203 Boehringer Ingelheim Investigational Site
Akron, Ohio, United States
1160.26.0434 Boehringer Ingelheim Investigational Site
Canal Fulton, Ohio, United States
1160.26.0083 Boehringer Ingelheim Investigational Site
Cincinnati, Ohio, United States
1160.26.0402 Boehringer Ingelheim Investigational Site
Cincinnati, Ohio, United States
1160.26.0426 Boehringer Ingelheim Investigational Site
Cincinnati, Ohio, United States
1160.26.0479 Boehringer Ingelheim Investigational Site
Cincinnati, Ohio, United States
1160.26.0263 Boehringer Ingelheim Investigational Site
Cleveland, Ohio, United States
1160.26.0480 Boehringer Ingelheim Investigational Site
Cleveland, Ohio, United States
1160.26.0267 Boehringer Ingelheim Investigational Site
Columbus, Ohio, United States
1160.26.0035 Boehringer Ingelheim Investigational Site
Dayton, Ohio, United States
1160.26.0150 Boehringer Ingelheim Investigational Site
Fairview Park, Ohio, United States
1160.26.0201 Boehringer Ingelheim Investigational Site
Kettering, Ohio, United States
1160.26.0223 Boehringer Ingelheim Investigational Site
Lorain, Ohio, United States
1160.26.0214 Boehringer Ingelheim Investigational Site
Lyndhurst, Ohio, United States
1160.26.0275 Boehringer Ingelheim Investigational Site
Sandusky, Ohio, United States
1160.26.0103 Boehringer Ingelheim Investigational Site
Westlake, Ohio, United States
1160.26.0155 Boehringer Ingelheim Investigational Site
Bartlesville, Oklahoma, United States
1160.26.0435 Boehringer Ingelheim Investigational Site
Tulsa, Oklahoma, United States
1160.26.0139 Boehringer Ingelheim Investigational Site
Corvallis, Oregon, United States
1160.26.0325 Boehringer Ingelheim Investigational Site
Eugene, Oregon, United States
1160.26.0078 Boehringer Ingelheim Investigational Site
Hillsboro, Oregon, United States
1160.26.0245 Boehringer Ingelheim Investigational Site
Portland, Oregon, United States
1160.26.0133 Boehringer Ingelheim Investigational Site
Springfield, Oregon, United States
1160.26.0301 Boehringer Ingelheim Investigational Site
Allentown, Pennsylvania, United States
1160.26.0454 Boehringer Ingelheim Investigational Site
Altoona, Pennsylvania, United States
1160.26.0295 Boehringer Ingelheim Investigational Site
Camp Hill, Pennsylvania, United States
1160.26.0294 Boehringer Ingelheim Investigational Site
Hershey, Pennsylvania, United States
1160.26.0369 Boehringer Ingelheim Investigational Site
Jenkintown, Pennsylvania, United States
1160.26.0303 Boehringer Ingelheim Investigational Site
Jersey Shore, Pennsylvania, United States
1160.26.0431 Boehringer Ingelheim Investigational Site
Lancaster, Pennsylvania, United States
1160.26.0168 Boehringer Ingelheim Investigational Site
Langhorne, Pennsylvania, United States
1160.26.0293 Boehringer Ingelheim Investigational Site
Meadowbrook, Pennsylvania, United States
1160.26.0025 Boehringer Ingelheim Investigational Site
Newton, Pennsylvania, United States
1160.26.0394 Boehringer Ingelheim Investigational Site
Norristown, Pennsylvania, United States
1160.26.0158 Boehringer Ingelheim Investigational Site
Philadelphia, Pennsylvania, United States
1160.26.0181 Boehringer Ingelheim Investigational Site
Philadelphia, Pennsylvania, United States
1160.26.0416 Boehringer Ingelheim Investigational Site
Philadelphia, Pennsylvania, United States
1160.26.0344 Boehringer Ingelheim Investigational Site
Pittsburgh, Pennsylvania, United States
1160.26.0466 Boehringer Ingelheim Investigational Site
Pittsburgh, Pennsylvania, United States
1160.26.0208 Boehringer Ingelheim Investigational Site
Sellersville, Pennsylvania, United States
1160.26.0465 Boehringer Ingelheim Investigational Site
Uniontown, Pennsylvania, United States
1160.26.0400 Boehringer Ingelheim Investigational Site
Upland, Pennsylvania, United States
1160.26.0032 Boehringer Ingelheim Investigational Site
Wynnewood, Pennsylvania, United States
1160.26.0067 Boehringer Ingelheim Investigational Site
Wyomissing, Pennsylvania, United States
1160.26.0212 Boehringer Ingelheim Investigational Site
Pawtucket, Rhode Island, United States
1160.26.0007 Boehringer Ingelheim Investigational Site
Beaufort, South Carolina, United States
1160.26.0383 Boehringer Ingelheim Investigational Site
Charleston, South Carolina, United States
1160.26.0313 Boehringer Ingelheim Investigational Site
Greenville, South Carolina, United States
1160.26.0450 Boehringer Ingelheim Investigational Site
Mt. Pleasant, South Carolina, United States
1160.26.0166 Boehringer Ingelheim Investigational Site
Spartanburg, South Carolina, United States
1160.26.0008 Boehringer Ingelheim Investigational Site
Summerville, South Carolina, United States
1160.26.0468 Boehringer Ingelheim Investigational Site
West Columbia, South Carolina, United States
1160.26.0348 Boehringer Ingelheim Investigational Site
Rapid City, South Dakota, United States
1160.26.0084 Boehringer Ingelheim Investigational Site
Chattanooga, Tennessee, United States
1160.26.0062 Boehringer Ingelheim Investigational Site
Germantown, Tennessee, United States
1160.26.0370 Boehringer Ingelheim Investigational Site
Johnson City, Tennessee, United States
1160.26.0323 Boehringer Ingelheim Investigational Site
Nashville, Tennessee, United States
1160.26.0395 Boehringer Ingelheim Investigational Site
Nashville, Tennessee, United States
1160.26.0474 Boehringer Ingelheim Investigational Site
Oak Ridge, Tennessee, United States
1160.26.0129 Boehringer Ingelheim Investigational Site
Austin, Texas, United States
1160.26.0410 Boehringer Ingelheim Investigational Site
Austin, Texas, United States
1160.26.0156 Boehringer Ingelheim Investigational Site
Dallas, Texas, United States
1160.26.0315 Boehringer Ingelheim Investigational Site
Fort Worth, Texas, United States
1160.26.0444 Boehringer Ingelheim Investigational Site
Fort Worth, Texas, United States
1160.26.0447 Boehringer Ingelheim Investigational Site
Houston, Texas, United States
1160.26.0483 Boehringer Ingelheim Investigational Site
Killeen, Texas, United States
1160.26.0335 Boehringer Ingelheim Investigational Site
Lubbock, Texas, United States
1160.26.0230 Boehringer Ingelheim Investigational Site
McKinney, Texas, United States
1160.26.0467 Boehringer Ingelheim Investigational Site
Plano, Texas, United States
1160.26.0013 Boehringer Ingelheim Investigational Site
San Antonio, Texas, United States
1160.26.0269 Boehringer Ingelheim Investigational Site
San Antonio, Texas, United States
1160.26.0307 Boehringer Ingelheim Investigational Site
San Antonio, Texas, United States
1160.26.0285 Boehringer Ingelheim Investigational Site
San Marcos, Texas, United States
1160.26.0215 Boehringer Ingelheim Investigational Site
Tyler, Texas, United States
1160.26.0367 Boehringer Ingelheim Investigational Site
Tyler, Texas, United States
1160.26.0195 Boehringer Ingelheim Investigational Site
Arlington, Virginia, United States
1160.26.0453 Boehringer Ingelheim Investigational Site
Charlottesville, Virginia, United States
1160.26.0053 Boehringer Ingelheim Investigational Site
Chesapeake, Virginia, United States
1160.26.0098 Boehringer Ingelheim Investigational Site
Danville, Virginia, United States
1160.26.0386 Boehringer Ingelheim Investigational Site
Falls Church, Virginia, United States
1160.26.0428 Boehringer Ingelheim Investigational Site
Fredericksburg, Virginia, United States
1160.26.0311 Boehringer Ingelheim Investigational Site
Harrisonburg, Virginia, United States
1160.26.0292 Boehringer Ingelheim Investigational Site
Newport News, Virginia, United States
1160.26.0224 Boehringer Ingelheim Investigational Site
Norfolk, Virginia, United States
1160.26.0220 Boehringer Ingelheim Investigational Site
Salem, Virginia, United States
1160.26.0317 Boehringer Ingelheim Investigational Site
Winchester, Virginia, United States
1160.26.0287 Boehringer Ingelheim Investigational Site
Bellevue, Washington, United States
1160.26.0050 Boehringer Ingelheim Investigational Site
Bellingham, Washington, United States
1160.26.0040 Boehringer Ingelheim Investigational Site
Burien, Washington, United States
1160.26.0298 Boehringer Ingelheim Investigational Site
Olympia, Washington, United States
1160.26.0250 Boehringer Ingelheim Investigational Site
Spokane, Washington, United States
1160.26.0256 Boehringer Ingelheim Investigational Site
Tacoma, Washington, United States
1160.26.0024 Boehringer Ingelheim Investigational Site
Wenatchee, Washington, United States
1160.26.0193 Boehringer Ingelheim Investigational Site
Charleston, West Virginia, United States
1160.26.0169 Boehringer Ingelheim Investigational Site
Clarksburg, West Virginia, United States
1160.26.0365 Boehringer Ingelheim Investigational Site
Huntington, West Virginia, United States
1160.26.0072 Boehringer Ingelheim Investigational Site
Elkhorn, Wisconsin, United States
1160.26.0234 Boehringer Ingelheim Investigational Site
Green Bay, Wisconsin, United States
1160.26.0099 Boehringer Ingelheim Investigational Site
Madison, Wisconsin, United States
1160.26.0242 Boehringer Ingelheim Investigational Site
Madison, Wisconsin, United States
1160.26.0359 Boehringer Ingelheim Investigational Site
Marshfield, Wisconsin, United States
1160.26.0461 Boehringer Ingelheim Investigational Site
Milwaukee, Wisconsin, United States
1160.26.0523 Boehringer Ingelheim Investigational Site
BahÃa Blanca, , Argentina
1160.26.0524 Boehringer Ingelheim Investigational Site
Capital Federal, , Argentina
1160.26.0533 Boehringer Ingelheim Investigational Site
Capital Federal, , Argentina
1160.26.0526 Boehringer Ingelheim Investigational Site
Cipolletti, , Argentina
1160.26.0529 Boehringer Ingelheim Investigational Site
Coronel Suárez, , Argentina
1160.26.0531 Boehringer Ingelheim Investigational Site
Córdoba, , Argentina
1160.26.0530 Boehringer Ingelheim Investigational Site
La Plata, , Argentina
1160.26.0527 Boehringer Ingelheim Investigational Site
Mar del Plata, , Argentina
1160.26.0532 Boehringer Ingelheim Investigational Site
Mar del Plata, , Argentina
1160.26.0525 Boehringer Ingelheim Investigational Site
Quilmes, , Argentina
1160.26.0521 Boehringer Ingelheim Investigational Site
Rosario, , Argentina
1160.26.0528 Boehringer Ingelheim Investigational Site
Salta, , Argentina
1160.26.0522 Boehringer Ingelheim Investigational Site
Santa Fe, , Argentina
1160.26.0508 Boehringer Ingelheim Investigational Site
Coffs Harbour, New South Wales, Australia
1160.26.0510 Boehringer Ingelheim Investigational Site
Gosford, New South Wales, Australia
1160.26.0505 Boehringer Ingelheim Investigational Site
Herston, Queensland, Australia
1160.26.0506 Boehringer Ingelheim Investigational Site
Milton, Queensland, Australia
1160.26.0509 Boehringer Ingelheim Investigational Site
Ashford, South Australia, Australia
1160.26.0507 Boehringer Ingelheim Investigational Site
Launceston, Tasmania, Australia
1160.26.0504 Boehringer Ingelheim Investigational Site
Box Hill, Victoria, Australia
1160.26.0501 Boehringer Ingelheim Investigational Site
Geelong, Victoria, Australia
1160.26.0502 Boehringer Ingelheim Investigational Site
Parkville, Victoria, Australia
1160.26.0503 Boehringer Ingelheim Investigational Site
Prahran, Victoria, Australia
1160.26.0543 Boehringer Ingelheim Investigational Site
Graz, , Austria
1160.26.0549 Boehringer Ingelheim Investigational Site
Linz, , Austria
1160.26.0541 Boehringer Ingelheim Investigational Site
Vienna, , Austria
1160.26.0542 Boehringer Ingelheim Investigational Site
Vienna, , Austria
1160.26.0544 Boehringer Ingelheim Investigational Site
Vienna, , Austria
1160.26.0545 Boehringer Ingelheim Investigational Site
Vienna, , Austria
1160.26.0547 Boehringer Ingelheim Investigational Site
Vienna, , Austria
1160.26.0548 Boehringer Ingelheim Investigational Site
Vienna, , Austria
1160.26.0546 Boehringer Ingelheim Investigational Site
Wels, , Austria
1160.26.0550 Boehringer Ingelheim Investigational Site
Wiener Neustadt, , Austria
1160.26.0564 Boehringer Ingelheim Investigational Site
Aalst, , Belgium
1160.26.0573 Boehringer Ingelheim Investigational Site
Antwerp, , Belgium
1160.26.0575 Boehringer Ingelheim Investigational Site
Antwerp, , Belgium
1160.26.0572 Boehringer Ingelheim Investigational Site
Brasschaat, , Belgium
1160.26.0577 Boehringer Ingelheim Investigational Site
Bruges, , Belgium
1160.26.0571 Boehringer Ingelheim Investigational Site
Brussels, , Belgium
1160.26.0581 Boehringer Ingelheim Investigational Site
Brussels, , Belgium
1160.26.0585 Boehringer Ingelheim Investigational Site
Brussels, , Belgium
1160.26.0586 Boehringer Ingelheim Investigational Site
Brussels, , Belgium
1160.26.0563 Boehringer Ingelheim Investigational Site
Edegem, , Belgium
1160.26.0578 Boehringer Ingelheim Investigational Site
Genk, , Belgium
1160.26.0587 Boehringer Ingelheim Investigational Site
Genk, , Belgium
1160.26.0574 Boehringer Ingelheim Investigational Site
Ghent, , Belgium
1160.26.0588 Boehringer Ingelheim Investigational Site
Gilly, , Belgium
1160.26.0580 Boehringer Ingelheim Investigational Site
Haine-St.-Paul, , Belgium
1160.26.0568 Boehringer Ingelheim Investigational Site
Hasselt, , Belgium
1160.26.0569 Boehringer Ingelheim Investigational Site
Kortrijk, , Belgium
1160.26.0561 Boehringer Ingelheim Investigational Site
Leuven, , Belgium
1160.26.0579 Boehringer Ingelheim Investigational Site
Liège, , Belgium
1160.26.0583 Boehringer Ingelheim Investigational Site
Liège, , Belgium
1160.26.0589 Boehringer Ingelheim Investigational Site
Mol, , Belgium
1160.26.0567 Boehringer Ingelheim Investigational Site
Ostend, , Belgium
1160.26.0570 Boehringer Ingelheim Investigational Site
Roeselare, , Belgium
1160.26.0566 Boehringer Ingelheim Investigational Site
Tienen, , Belgium
1160.26.0562 Boehringer Ingelheim Investigational Site
Turnhout, , Belgium
1160.26.550648 Boehringer Ingelheim Investigational Site
Belo Horizonte, , Brazil
1160.26.550654 Boehringer Ingelheim Investigational Site
Blumenau, , Brazil
1160.26.550644 Boehringer Ingelheim Investigational Site
Campinas, , Brazil
1160.26.550650 Boehringer Ingelheim Investigational Site
Curitiba, , Brazil
1160.26.550651 Boehringer Ingelheim Investigational Site
Curitiba, , Brazil
1160.26.550653 Boehringer Ingelheim Investigational Site
Curitiba, , Brazil
1160.26.550652 Boehringer Ingelheim Investigational Site
Goiânia, , Brazil
1160.26.550645 Boehringer Ingelheim Investigational Site
MarÃlia, , Brazil
1160.26.550646 Boehringer Ingelheim Investigational Site
São José do Rio Preto, , Brazil
1160.26.550647 Boehringer Ingelheim Investigational Site
São José do Rio Preto, , Brazil
1160.26.550641 Boehringer Ingelheim Investigational Site
São Paulo, , Brazil
1160.26.550642 Boehringer Ingelheim Investigational Site
São Paulo, , Brazil
1160.26.550643 Boehringer Ingelheim Investigational Site
São Paulo, , Brazil
1160.26.550649 Boehringer Ingelheim Investigational Site
Uberaba, , Brazil
1160.26.0620 Boehringer Ingelheim Investigational Site
Pleven, , Bulgaria
1160.26.0611 Boehringer Ingelheim Investigational Site
Sofia, , Bulgaria
1160.26.0612 Boehringer Ingelheim Investigational Site
Sofia, , Bulgaria
1160.26.0613 Boehringer Ingelheim Investigational Site
Sofia, , Bulgaria
1160.26.0614 Boehringer Ingelheim Investigational Site
Sofia, , Bulgaria
1160.26.0615 Boehringer Ingelheim Investigational Site
Sofia, , Bulgaria
1160.26.0616 Boehringer Ingelheim Investigational Site
Sofia, , Bulgaria
1160.26.0617 Boehringer Ingelheim Investigational Site
Sofia, , Bulgaria
1160.26.0618 Boehringer Ingelheim Investigational Site
Sofia, , Bulgaria
1160.26.0622 Boehringer Ingelheim Investigational Site
Sofia, , Bulgaria
1160.26.0623 Boehringer Ingelheim Investigational Site
Sofia, , Bulgaria
1160.26.0624 Boehringer Ingelheim Investigational Site
Sofia, , Bulgaria
1160.26.0625 Boehringer Ingelheim Investigational Site
Sofia, , Bulgaria
1160.26.0626 Boehringer Ingelheim Investigational Site
Stara Zagora, , Bulgaria
1160.26.0621 Boehringer Ingelheim Investigational Site
Varna, , Bulgaria
1160.26.0694 Boehringer Ingelheim Investigational Site
Calgary, Alberta, Canada
1160.26.0696 Boehringer Ingelheim Investigational Site
Calgary, Alberta, Canada
1160.26.0680 Boehringer Ingelheim Investigational Site
Coquitlam, British Columbia, Canada
1160.26.0712 Boehringer Ingelheim Investigational Site
Coquitlam, British Columbia, Canada
1160.26.0706 Boehringer Ingelheim Investigational Site
Kelowna, British Columbia, Canada
1160.26.0725 Boehringer Ingelheim Investigational Site
Nanaimo, British Columbia, Canada
1160.26.0691 Boehringer Ingelheim Investigational Site
New Westminster, British Columbia, Canada
1160.26.0714 Boehringer Ingelheim Investigational Site
Victoria, British Columbia, Canada
1160.26.0701 Boehringer Ingelheim Investigational Site
Portage la Prairie, Manitoba, Canada
1160.26.0698 Boehringer Ingelheim Investigational Site
Winnipeg, Manitoba, Canada
1160.26.0707 Boehringer Ingelheim Investigational Site
Bay Roberts, Newfoundland and Labrador, Canada
1160.26.0676 Boehringer Ingelheim Investigational Site
Antigonish, Nova Scotia, Canada
1160.26.0703 Boehringer Ingelheim Investigational Site
Halifax, Nova Scotia, Canada
1160.26.0679 Boehringer Ingelheim Investigational Site
Ajax, Ontario, Canada
1160.26.0677 Boehringer Ingelheim Investigational Site
Brampton, Ontario, Canada
1160.26.0674 Boehringer Ingelheim Investigational Site
Burlington, Ontario, Canada
1160.26.0702 Boehringer Ingelheim Investigational Site
Cambridge, Ontario, Canada
1160.26.0720 Boehringer Ingelheim Investigational Site
Cambridge, Ontario, Canada
1160.26.0671 Clinical Research & Diagnostic Solutions Inc.
Etobicoke, Ontario, Canada
1160.26.0715 Boehringer Ingelheim Investigational Site
Greater Sudbury, Ontario, Canada
1160.26.0692 Boehringer Ingelheim Investigational Site
Grimsby, Ontario, Canada
1160.26.0685 Boehringer Ingelheim Investigational Site
Hamilton, Ontario, Canada
1160.26.0697 Boehringer Ingelheim Investigational Site
Hamilton, Ontario, Canada
1160.26.0710 Boehringer Ingelheim Investigational Site
Hamilton, Ontario, Canada
1160.26.0719 Boehringer Ingelheim Investigational Site
Hamilton, Ontario, Canada
1160.26.0721 Boehringer Ingelheim Investigational Site
Hamilton, Ontario, Canada
1160.26.0689 Boehringer Ingelheim Investigational Site
Kitchener, Ontario, Canada
1160.26.0695 Boehringer Ingelheim Investigational Site
Mississauga, Ontario, Canada
1160.26.0708 Boehringer Ingelheim Investigational Site
Mississauga, Ontario, Canada
1160.26.0724 Boehringer Ingelheim Investigational Site
Mississauga, Ontario, Canada
1160.26.0688 Boehringer Ingelheim Investigational Site
Newmarket, Ontario, Canada
1160.26.0672 Boehringer Ingelheim Investigational Site
Oshawa, Ontario, Canada
1160.26.0687 Boehringer Ingelheim Investigational Site
Ottawa, Ontario, Canada
1160.26.0723 Boehringer Ingelheim Investigational Site
Scarborough Village, Ontario, Canada
1160.26.0690 Boehringer Ingelheim Investigational Site
Thunder Bay, Ontario, Canada
1160.26.0684 Boehringer Ingelheim Investigational Site
Toronto, Ontario, Canada
1160.26.0718 Boehringer Ingelheim Investigational Site
Toronto, Ontario, Canada
1160.26.0711 Boehringer Ingelheim Investigational Site
Waterloo, Ontario, Canada
1160.26.0686 Boehringer Ingelheim Investigational Site
Windsor, Ontario, Canada
1160.26.0693 Boehringer Ingelheim Investigational Site
Longueuil, Quebec, Canada
1160.26.0681 Boehringer Ingelheim Investigational Site
Montreal, Quebec, Canada
1160.26.0683 Boehringer Ingelheim Investigational Site
Montreal, Quebec, Canada
1160.26.0705 Boehringer Ingelheim Investigational Site
Montreal, Quebec, Canada
1160.26.0709 Boehringer Ingelheim Investigational Site
Montreal, Quebec, Canada
1160.26.0716 Boehringer Ingelheim Investigational Site
Montreal, Quebec, Canada
1160.26.0717 Boehringer Ingelheim Investigational Site
Québec, Quebec, Canada
1160.26.0713 Boehringer Ingelheim Investigational Site
Saint George-de-Beauce, Quebec, Canada
1160.26.0699 Boehringer Ingelheim Investigational Site
Saint-Charles-Borromée, Quebec, Canada
1160.26.0675 Boehringer Ingelheim Investigational Site
Saint-Hyacinthe, Quebec, Canada
1160.26.0704 Boehringer Ingelheim Investigational Site
Saint-Jérôme, Quebec, Canada
1160.26.0700 Boehringer Ingelheim Investigational Site
Ste-Foy, Quebec, Canada
1160.26.0682 Boehringer Ingelheim Investigational Site
Terrebonne (Lachenaie), Quebec, Canada
1160.26.0673 Boehringer Ingelheim Investigational Site
Saskatoon, Saskatchewan, Canada
1160.26.0678 Boehringer Ingelheim Investigational Site
Saskatoon, Saskatchewan, Canada
1160.26.0771 Boehringer Ingelheim Investigational Site
Beijing, , China
1160.26.0772 Boehringer Ingelheim Investigational Site
Beijing, , China
1160.26.0773 Boehringer Ingelheim Investigational Site
Beijing, , China
1160.26.0774 Boehringer Ingelheim Investigational Site
Beijing, , China
1160.26.0775 Boehringer Ingelheim Investigational Site
Beijing, , China
1160.26.0783 Boehringer Ingelheim Investigational Site
Beijing, , China
1160.26.0784 Boehringer Ingelheim Investigational Site
Hangzhou, , China
1160.26.0776 Boehringer Ingelheim Investigational Site
Harbin, , China
1160.26.0778 Boehringer Ingelheim Investigational Site
Qingdao, , China
1160.26.0781 Boehringer Ingelheim Investigational Site
Shanghai, , China
1160.26.0782 Boehringer Ingelheim Investigational Site
Shanghai, , China
1160.26.0777 Boehringer Ingelheim Investigational Site
Shenyang, , China
1160.26.0780 Boehringer Ingelheim Investigational Site
Shijiazhuang, , China
1160.26.0801 Boehringer Ingelheim Investigational Site
Bogotá, , Colombia
1160.26.0802 Boehringer Ingelheim Investigational Site
Bogotá, , Colombia
1160.26.0803 Boehringer Ingelheim Investigational Site
Bogotá, , Colombia
1160.26.0815 Boehringer Ingelheim Investigational Site
Brno, , Czechia
1160.26.0816 Boehringer Ingelheim Investigational Site
Brno, , Czechia
1160.26.0820 Boehringer Ingelheim Investigational Site
Ostrava, , Czechia
1160.26.0818 Boehringer Ingelheim Investigational Site
Pardubice, , Czechia
1160.26.0814 Boehringer Ingelheim Investigational Site
Plzen-Bory, , Czechia
1160.26.0813 Boehringer Ingelheim Investigational Site
Pragha 9, , Czechia
1160.26.0811 Boehringer Ingelheim Investigational Site
Prague, , Czechia
1160.26.0812 Boehringer Ingelheim Investigational Site
Prague, , Czechia
1160.26.0817 Boehringer Ingelheim Investigational Site
PÅ™Ãbram, , Czechia
1160.26.0819 Boehringer Ingelheim Investigational Site
Ústà nad OrlicÃ, , Czechia
1160.26.0837 Boehringer Ingelheim Investigational Site
Aalborg, , Denmark
1160.26.0835 Boehringer Ingelheim Investigational Site
Aarhus C, , Denmark
1160.26.0833 Boehringer Ingelheim Investigational Site
Elsinore, , Denmark
1160.26.0838 Boehringer Ingelheim Investigational Site
Frederikssund, , Denmark
1160.26.0834 Boehringer Ingelheim Investigational Site
Herlev, , Denmark
1160.26.0841 Boehringer Ingelheim Investigational Site
Horsens, , Denmark
1160.26.0832 Boehringer Ingelheim Investigational Site
Hvidovre, , Denmark
1160.26.0840 Boehringer Ingelheim Investigational Site
Køge, , Denmark
1160.26.0831 Boehringer Ingelheim Investigational Site
Odense, , Denmark
1160.26.0839 Boehringer Ingelheim Investigational Site
Roskilde, , Denmark
1160.26.0836 Boehringer Ingelheim Investigational Site
Svendborg, , Denmark
1160.26.0856 Boehringer Ingelheim Investigational Site
Espoo, , Finland
1160.26.0851 Boehringer Ingelheim Investigational Site
HUS, , Finland
1160.26.0859 Boehringer Ingelheim Investigational Site
Jyväskylä, , Finland
1160.26.0855 Boehringer Ingelheim Investigational Site
Kuopio, , Finland
1160.26.0857 Boehringer Ingelheim Investigational Site
Lappeenranta, , Finland
1160.26.0854 Boehringer Ingelheim Investigational Site
OYS, , Finland
1160.26.0858 Boehringer Ingelheim Investigational Site
Pori, , Finland
1160.26.0852 Boehringer Ingelheim Investigational Site
Tampere, , Finland
1160.26.0853 Boehringer Ingelheim Investigational Site
Turku, , Finland
1160.26.0875A Boehringer Ingelheim Investigational Site
Abbeville, , France
1160.26.0882A Boehringer Ingelheim Investigational Site
Angers, , France
1160.26.0882B Boehringer Ingelheim Investigational Site
Angers, , France
1160.26.0882C Boehringer Ingelheim Investigational Site
Angers, , France
1160.26.0882D Boehringer Ingelheim Investigational Site
Angers, , France
1160.26.0882E Boehringer Ingelheim Investigational Site
Angers, , France
1160.26.0882G Boehringer Ingelheim Investigational Site
Angers, , France
1160.26.0882H Boehringer Ingelheim Investigational Site
Angers, , France
1160.26.0882I Boehringer Ingelheim Investigational Site
Angers, , France
1160.26.0882K Boehringer Ingelheim Investigational Site
Angers, , France
1160.26.0882L Boehringer Ingelheim Investigational Site
Angers, , France
1160.26.0884A Boehringer Ingelheim Investigational Site
Angers, , France
1160.26.0887A Boehringer Ingelheim Investigational Site
Cholet, , France
1160.26.0889A Boehringer Ingelheim Investigational Site
Gap, , France
1160.26.0888A Boehringer Ingelheim Investigational Site
Grenoble, , France
1160.26.0880B Boehringer Ingelheim Investigational Site
Joué Les Tours, , France
1160.26.0880C Boehringer Ingelheim Investigational Site
Joué Les Tours, , France
1160.26.0880D Boehringer Ingelheim Investigational Site
Joué Les Tours, , France
1160.26.0880E Boehringer Ingelheim Investigational Site
Joué Les Tours, , France
1160.26.0879A Boehringer Ingelheim Investigational Site
Joué-lès-Tours, , France
1160.26.0879B Boehringer Ingelheim Investigational Site
Joué-lès-Tours, , France
1160.26.0879C Boehringer Ingelheim Investigational Site
Joué-lès-Tours, , France
1160.26.0879E Boehringer Ingelheim Investigational Site
Joué-lès-Tours, , France
1160.26.0879F Boehringer Ingelheim Investigational Site
Joué-lès-Tours, , France
1160.26.0879G Boehringer Ingelheim Investigational Site
Joué-lès-Tours, , France
1160.26.0879H Boehringer Ingelheim Investigational Site
Joué-lès-Tours, , France
1160.26.0879S Boehringer Ingelheim Investigational Site
Joué-lès-Tours, , France
1160.26.0880A Boehringer Ingelheim Investigational Site
Joué-lès-Tours, , France
1160.26.0880F Boehringer Ingelheim Investigational Site
Joué-lès-Tours, , France
1160.26.0880G Boehringer Ingelheim Investigational Site
Joué-lès-Tours, , France
1160.26.0880J Boehringer Ingelheim Investigational Site
Joué-lès-Tours, , France
1160.26.0881A Boehringer Ingelheim Investigational Site
Joué-lès-Tours, , France
1160.26.0881D Boehringer Ingelheim Investigational Site
Joué-lès-Tours, , France
1160.26.0874A Boehringer Ingelheim Investigational Site
Langres, , France
1160.26.0874B Boehringer Ingelheim Investigational Site
Langres, , France
1160.26.0871A Boehringer Ingelheim Investigational Site
Paris, , France
1160.26.0873A Boehringer Ingelheim Investigational Site
Toulouse, , France
1160.26.0886A Boehringer Ingelheim Investigational Site
Tourcoing, , France
1160.26.0872A Boehringer Ingelheim Investigational Site
Valenciennes, , France
1160.26.0872B Boehringer Ingelheim Investigational Site
Valenciennes, , France
1160.26.0872C Boehringer Ingelheim Investigational Site
Valenciennes, , France
1160.26.0932 Boehringer Ingelheim Investigational Site
Berlin, , Germany
1160.26.0948 Boehringer Ingelheim Investigational Site
Berlin, , Germany
1160.26.0962 Boehringer Ingelheim Investigational Site
Berlin, , Germany
1160.26.0940 Boehringer Ingelheim Investigational Site
Bochum, , Germany
1160.26.0936 Boehringer Ingelheim Investigational Site
Coburg, , Germany
1160.26.0963 Boehringer Ingelheim Investigational Site
Cologne, , Germany
1160.26.0968 Boehringer Ingelheim Investigational Site
Dachau, , Germany
1160.26.0972 Boehringer Ingelheim Investigational Site
Dortmund, , Germany
1160.26.0957 Boehringer Ingelheim Investigational Site
Duisburg, , Germany
1160.26.0971 Boehringer Ingelheim Investigational Site
Erlangen, , Germany
1160.26.0965 Boehringer Ingelheim Investigational Site
Eschweiler, , Germany
1160.26.0934 Boehringer Ingelheim Investigational Site
Essen, , Germany
1160.26.0931 Boehringer Ingelheim Investigational Site
Frankfurt am Main, , Germany
1160.26.0943 Boehringer Ingelheim Investigational Site
Heidelberg, , Germany
1160.26.0955 Boehringer Ingelheim Investigational Site
Kassel, , Germany
1160.26.0946 Boehringer Ingelheim Investigational Site
Lahr, , Germany
1160.26.0944 Boehringer Ingelheim Investigational Site
Limburg, , Germany
1160.26.0951 Boehringer Ingelheim Investigational Site
Mainz, , Germany
1160.26.0933 Boehringer Ingelheim Investigational Site
Mannheim, , Germany
1160.26.0945 Boehringer Ingelheim Investigational Site
Mannheim, , Germany
1160.26.0970 Boehringer Ingelheim Investigational Site
Mannheim, , Germany
1160.26.0947 Boehringer Ingelheim Investigational Site
München, , Germany
1160.26.0952 Boehringer Ingelheim Investigational Site
München, , Germany
1160.26.0941 Boehringer Ingelheim Investigational Site
Papenburg, , Germany
1160.26.0959 Boehringer Ingelheim Investigational Site
Suhl, , Germany
1160.26.0937 Boehringer Ingelheim Investigational Site
Witten, , Germany
1160.26.0966 Boehringer Ingelheim Investigational Site
Wuppertal, , Germany
1160.26.0908 University Hospital of Alexandroupolis
Alexandroupoli, , Greece
1160.26.0901 General Hospital "Alexandra", Therapeutic Clinic UOA
Athens, , Greece
1160.26.0906 General Hospital ";Evangelismos"
Athens, , Greece
1160.26.0907 "Pammakaristos" Hospital of Athens
Athens, , Greece
1160.26.0915 "Hippokratio" Hospital of Athens
Athens, , Greece
1160.26.0914 2nd IKA Hospital, Thessaloniki
Kalamaria-Thessaloniki, , Greece
1160.26.0904 General Hospital of Larissa
Larissa, , Greece
1160.26.0913 University Hospital of Larissa
Larissa, , Greece
1160.26.0912 General Hospital of Leivadia
Livadeia, , Greece
1160.26.0910 General Hospital of Thiva
Thebes, , Greece
1160.26.0902 General Hospital " Papageorgiou"
Thessaloniki, , Greece
1160.26.0903 General Hospital of Trikala
Trikala, , Greece
1160.26.0905 Boehringer Ingelheim Investigational Site
Voula - Athens, , Greece
1160.26.1001 Boehringer Ingelheim Investigational Site
Hong Kong, , Hong Kong
1160.26.1002 Boehringer Ingelheim Investigational Site
Hong Kong, , Hong Kong
1160.26.1003 Boehringer Ingelheim Investigational Site
Kowloon, , Hong Kong
1160.26.1004 Boehringer Ingelheim Investigational Site
Kowloon, , Hong Kong
1160.26.1011 Boehringer Ingelheim Investigational Site
Budapest, , Hungary
1160.26.1012 Boehringer Ingelheim Investigational Site
Budapest, , Hungary
1160.26.1013 Boehringer Ingelheim Investigational Site
Budapest, , Hungary
1160.26.1014 Boehringer Ingelheim Investigational Site
Budapest, , Hungary
1160.26.1015 Boehringer Ingelheim Investigational Site
Budapest, , Hungary
1160.26.1016 Boehringer Ingelheim Investigational Site
Budapest, , Hungary
1160.26.1020 Boehringer Ingelheim Investigational Site
Gyöngyös, , Hungary
1160.26.1017 Boehringer Ingelheim Investigational Site
Komárom, , Hungary
1160.26.1018 Boehringer Ingelheim Investigational Site
Pécs, , Hungary
1160.26.1019 Boehringer Ingelheim Investigational Site
Veszprém, , Hungary
1160.26.1056 Boehringer Ingelheim Investigational Site
Ahmedabad, , India
1160.26.1057 Boehringer Ingelheim Investigational Site
Ahmedabad, , India
1160.26.1064 Boehringer Ingelheim Investigational Site
Bangalore, , India
1160.26.1065 Boehringer Ingelheim Investigational Site
Bangalore, , India
1160.26.1071 Boehringer Ingelheim Investigational Site
Bikaner, , India
1160.26.1066 Boehringer Ingelheim Investigational Site
Chennai, , India
1160.26.1069 Boehringer Ingelheim Investigational Site
Coimbatore, , India
1160.26.1062 Boehringer Ingelheim Investigational Site
Hyderabad, , India
1160.26.1058 Boehringer Ingelheim Investigational Site
Indore, , India
1160.26.1053 Boehringer Ingelheim Investigational Site
Jaipur, , India
1160.26.1073 Boehringer Ingelheim Investigational Site
Jaipur, , India
1160.26.1067 Boehringer Ingelheim Investigational Site
Kerala, , India
1160.26.1068 Boehringer Ingelheim Investigational Site
Kottayam, , India
1160.26.1055 Boehringer Ingelheim Investigational Site
Lucknow, , India
1160.26.1051 Boehringer Ingelheim Investigational Site
Ludhiana, , India
1160.26.1060 Boehringer Ingelheim Investigational Site
Mumbai, , India
1160.26.1072 Boehringer Ingelheim Investigational Site
Mysore, , India
1160.26.1059 Boehringer Ingelheim Investigational Site
Nagpur, , India
1160.26.1052 Boehringer Ingelheim Investigational Site
New Delhi, , India
1160.26.1070 Boehringer Ingelheim Investigational Site
Pune, , India
1160.26.1110 Boehringer Ingelheim Investigational Site
Afula, , Israel
1160.26.1121 Boehringer Ingelheim Investigational Site
Afula, , Israel
1160.26.1111 Boehringer Ingelheim Investigational Site
Ashkelon, , Israel
1160.26.1102 Boehringer Ingelheim Investigational Site
Beersheba, , Israel
1160.26.1117 Boehringer Ingelheim Investigational Site
Giv‘atayim, , Israel
1160.26.1112 Boehringer Ingelheim Investigational Site
Hadera, , Israel
1160.26.1091 Boehringer Ingelheim Investigational Site
Haifa, , Israel
1160.26.1113 Boehringer Ingelheim Investigational Site
Haifa, , Israel
1160.26.1114 Boehringer Ingelheim Investigational Site
Haifa, , Israel
1160.26.1116 Boehringer Ingelheim Investigational Site
Haifa, , Israel
1160.26.1118 Boehringer Ingelheim Investigational Site
Haifa, , Israel
1160.26.1105 Boehringer Ingelheim Investigational Site
Holon, , Israel
1160.26.1097 Boehringer Ingelheim Investigational Site
Jerusalem, , Israel
1160.26.1101 Boehringer Ingelheim Investigational Site
Jerusalem, , Israel
1160.26.1104 Boehringer Ingelheim Investigational Site
Jerusalem, , Israel
1160.26.1106 Boehringer Ingelheim Investigational Site
Jerusalem, , Israel
1160.26.1119 Boehringer Ingelheim Investigational Site
Kfar Saba, , Israel
1160.26.1115 Boehringer Ingelheim Investigational Site
Nazareth, , Israel
1160.26.1096 Boehringer Ingelheim Investigational Site
Petah Tikva, , Israel
1160.26.1093 Boehringer Ingelheim Investigational Site
Ramat Gan, , Israel
1160.26.1094 Boehringer Ingelheim Investigational Site
Ramat Gan, , Israel
1160.26.1095 Boehringer Ingelheim Investigational Site
Ramat Gan, , Israel
1160.26.1100 Boehringer Ingelheim Investigational Site
Rehovot, , Israel
1160.26.1103 Boehringer Ingelheim Investigational Site
Safed, , Israel
1160.26.1107 Boehringer Ingelheim Investigational Site
Tel Aviv, , Israel
1160.26.1108 Boehringer Ingelheim Investigational Site
Tel Aviv, , Israel
1160.26.1109 Boehringer Ingelheim Investigational Site
Tel Aviv, , Israel
1160.26.1120 Boehringer Ingelheim Investigational Site
Tel Aviv, , Israel
1160.26.1122 Boehringer Ingelheim Investigational Site
Tel Aviv, , Israel
1160.26.1092 Boehringer Ingelheim Investigational Site
Tel Litwinsky, , Israel
1160.26.1098 Boehringer Ingelheim Investigational Site
Tel Litwinsky, , Israel
1160.26.1099 Boehringer Ingelheim Investigational Site
Ẕerifin, , Israel
1160.26.1169 Boehringer Ingelheim Investigational Site
Arezzo, , Italy
1160.26.1172 Boehringer Ingelheim Investigational Site
Ascoli Piceno, , Italy
1160.26.1180 Boehringer Ingelheim Investigational Site
Bentivoglio (BO), , Italy
1160.26.1161 Boehringer Ingelheim Investigational Site
Bologna, , Italy
1160.26.1163 Boehringer Ingelheim Investigational Site
Castelnuovo Garfagnana, , Italy
1160.26.1178 Boehringer Ingelheim Investigational Site
Chieti, , Italy
1160.26.1171 Boehringer Ingelheim Investigational Site
Colleferro, , Italy
1160.26.1174 Boehringer Ingelheim Investigational Site
Cremona, , Italy
1160.26.1167 Boehringer Ingelheim Investigational Site
Eboli, , Italy
1160.26.1168 Boehringer Ingelheim Investigational Site
Isernia, , Italy
1160.26.1162 Boehringer Ingelheim Investigational Site
Legnago, , Italy
1160.26.1177 Boehringer Ingelheim Investigational Site
Mantova, , Italy
1160.26.1165 Boehringer Ingelheim Investigational Site
Perugia SAN Sisto, , Italy
1160.26.1175 Boehringer Ingelheim Investigational Site
Roma, , Italy
1160.26.1181 Boehringer Ingelheim Investigational Site
San Bonifacio, , Italy
1160.26.1173 Boehringer Ingelheim Investigational Site
San Daniele del Friuli, , Italy
1160.26.1170 Boehringer Ingelheim Investigational Site
Sassari, , Italy
1160.26.1176 Boehringer Ingelheim Investigational Site
Sassari, , Italy
1160.26.1204 Boehringer Ingelheim Investigational Site
Abeno-ku, Osaka, Osaka, , Japan
1160.26.1209 Boehringer Ingelheim Investigational Site
Aki-gun, Hiroshima, , Japan
1160.26.1193 Boehringer Ingelheim Investigational Site
Aoba-ku, Sendai, Miyagi, , Japan
1160.26.1211 Boehringer Ingelheim Investigational Site
Chuo-ku, Fukuoka, Fukuoka, , Japan
1160.26.1225 Boehringer Ingelheim Investigational Site
Chuo-ku, Fukuoka, Fukuoka, , Japan
1160.26.1221 Boehringer Ingelheim Investigational Site
Chuo-ku, Kobe, Hyogo, , Japan
1160.26.1219 Boehringer Ingelheim Investigational Site
Chuo-ku, Osaka, Osaka, , Japan
1160.26.1229 Boehringer Ingelheim Investigational Site
Fujioka-shi , Gunma-ken, , Japan
1160.26.1232 Boehringer Ingelheim Investigational Site
Fukushima-shi,Fukushima-ken, , Japan
1160.26.1228 Boehringer Ingelheim Investigational Site
Higashimatsushimashi, Miyagi-ken, , Japan
1160.26.1208 Boehringer Ingelheim Investigational Site
Himeji, Hyogo, , Japan
1160.26.1214 Boehringer Ingelheim Investigational Site
Iida, Nagano, , Japan
1160.26.1240 Boehringer Ingelheim Investigational Site
Isesaki-shi,Gunma, , Japan
1160.26.1224 Boehringer Ingelheim Investigational Site
Iwakuni, Yamaguchi, , Japan
1160.26.1194 Boehringer Ingelheim Investigational Site
Izumi-ku, Sendai, Miyagi, , Japan
1160.26.1241 Boehringer Ingelheim Investigational Site
Kamigyo-ku, Kyoto, , Japan
1160.26.1220 Boehringer Ingelheim Investigational Site
Kawachinagano, Osaka, , Japan
1160.26.1203 Boehringer Ingelheim Investigational Site
Kita-ku, Osaka, Osaka, , Japan
1160.26.1207 Boehringer Ingelheim Investigational Site
Kita-ku, Sakai, Osaka, , Japan
1160.26.1231 Boehringer Ingelheim Investigational Site
Komatsu-shi,Ishikawa -ken, , Japan
1160.26.1233 Boehringer Ingelheim Investigational Site
Kyoto-shi,Kyoto, , Japan
1160.26.1242 Boehringer Ingelheim Investigational Site
Matsumoto, Nagano, , Japan
1160.26.1210 Boehringer Ingelheim Investigational Site
Minami-ku, Fukuoka, Fukuoka, , Japan
1160.26.1218 Boehringer Ingelheim Investigational Site
Minato, Tokyo, , Japan
1160.26.1200 Boehringer Ingelheim Investigational Site
Minato-ku, Nagoya, Aichi, , Japan
1160.26.1201 Boehringer Ingelheim Investigational Site
Minato-ku, Nagoya, Aichi, , Japan
1160.26.1216 Boehringer Ingelheim Investigational Site
Narashino, Chiba, , Japan
1160.26.1237 Boehringer Ingelheim Investigational Site
Nishinomiya-shi,Hyogo, , Japan
1160.26.1223 Boehringer Ingelheim Investigational Site
Okayama, Okayama, , Japan
1160.26.1197 Boehringer Ingelheim Investigational Site
Oota, Tokyo, , Japan
1160.26.1212 Boehringer Ingelheim Investigational Site
Otaru, Hokkaido, , Japan
1160.26.1230 Boehringer Ingelheim Investigational Site
Sagamihara, Kanagawa-ken, , Japan
1160.26.1238 Boehringer Ingelheim Investigational Site
Sapporo-shi,Hokkai-do, , Japan
1160.26.1217 Boehringer Ingelheim Investigational Site
Shibuya, Tokyo, , Japan
1160.26.1196 Boehringer Ingelheim Investigational Site
Shinjuku, Tokyo, , Japan
1160.26.1191 Boehringer Ingelheim Investigational Site
Shiroishi-ku, Sapporo, Hokkaido, , Japan
1160.26.1192 Boehringer Ingelheim Investigational Site
Shiroishi-ku, Sapporo, Hokkaido, , Japan
1160.26.1206 Boehringer Ingelheim Investigational Site
Suita, Osaka, , Japan
1160.26.1235 Boehringer Ingelheim Investigational Site
Suita-shi, Osaka, , Japan
1160.26.1236 Boehringer Ingelheim Investigational Site
Suita-shi, Osaka, , Japan
1160.26.1205 Boehringer Ingelheim Investigational Site
Sumiyoshi-ku, Osaka, Osaka, , Japan
1160.26.1234 Boehringer Ingelheim Investigational Site
Takatsuki-shi,Osaka, , Japan
1160.26.1215 Boehringer Ingelheim Investigational Site
Tokorozawa, Saitama, , Japan
1160.26.1198 Boehringer Ingelheim Investigational Site
Totsuka-ku, Yokohama, Kanagawa, , Japan
1160.26.1195 Boehringer Ingelheim Investigational Site
Tsuchiura, Ibaragi, , Japan
1160.26.1199 Boehringer Ingelheim Investigational Site
Ueda, Nagano, , Japan
1160.26.1222 Boehringer Ingelheim Investigational Site
Wakayama, Wakayama, , Japan
1160.26.1227 Boehringer Ingelheim Investigational Site
Yanagawa, Fukuoka, , Japan
1160.26.1243 Boehringer Ingelheim Investigational Site
Yao, Osaka, , Japan
1160.26.1295 Boehringer Ingelheim Investigational Site
George Town, , Malaysia
1160.26.1296 Boehringer Ingelheim Investigational Site
George Town, , Malaysia
1160.26.1297 Boehringer Ingelheim Investigational Site
Kajang,Selangor, , Malaysia
1160.26.1291 Boehringer Ingelheim Investigational Site
Kuala Lumpur, , Malaysia
1160.26.1292 Boehringer Ingelheim Investigational Site
Kuala Lumpur, , Malaysia
1160.26.1294 Boehringer Ingelheim Investigational Site
Kuala Lumpur, , Malaysia
1160.26.1293 Boehringer Ingelheim Investigational Site
Kuching, , Malaysia
1160.26.1318 Hospital General "Dr. Santiago Ramón y Cajal
Durango, , Mexico
1160.26.1311 Hospital Mexico-Americano
Guadalajara, , Mexico
1160.26.1317 hOSPITAL bERNARDETTE
Guadalajara, , Mexico
1160.26.1312 Hospital de Jesus
México, , Mexico
1160.26.1314 Hospital 1o. de Octubre
México, , Mexico
1160.26.1319 Instituto Nacional de Cardiologia
México, , Mexico
1160.26.1313 Hosp. Angeles Centro Medico del Potosi
San Luis Potosà City, , Mexico
1160.26.1322 Hospital Central "Dr. Ignacio Morones Prieto"
San Luis Potosà City, , Mexico
1160.26.1337 Boehringer Ingelheim Investigational Site
's-Hertogenbosch, , Netherlands
1160.26.1344 Boehringer Ingelheim Investigational Site
Almelo, , Netherlands
1160.26.1331 Boehringer Ingelheim Investigational Site
Amsterdam, , Netherlands
1160.26.1336 Boehringer Ingelheim Investigational Site
Apeldoorn, , Netherlands
1160.26.1332 Boehringer Ingelheim Investigational Site
Breda, , Netherlands
1160.26.1349 Boehringer Ingelheim Investigational Site
Den Helder, , Netherlands
1160.26.1345 Boehringer Ingelheim Investigational Site
Deventer, , Netherlands
1160.26.1360 Boehringer Ingelheim Investigational Site
Dirksland, , Netherlands
1160.26.1348 Boehringer Ingelheim Investigational Site
Dordrecht, , Netherlands
1160.26.1340 Boehringer Ingelheim Investigational Site
Ede, , Netherlands
1160.26.1358 Boehringer Ingelheim Investigational Site
Eindhoven, , Netherlands
1160.26.1338 Boehringer Ingelheim Investigational Site
Enschede, , Netherlands
1160.26.1343 Boehringer Ingelheim Investigational Site
Goes, , Netherlands
1160.26.1347 Boehringer Ingelheim Investigational Site
Gorinchem, , Netherlands
1160.26.1333 Boehringer Ingelheim Investigational Site
Groningen, , Netherlands
1160.26.1355 Boehringer Ingelheim Investigational Site
Groningen, , Netherlands
1160.26.1361 Boehringer Ingelheim Investigational Site
Heerlen, , Netherlands
1160.26.1339 Boehringer Ingelheim Investigational Site
Hengelo, , Netherlands
1160.26.1346 Boehringer Ingelheim Investigational Site
Hilversum, , Netherlands
1160.26.1356 Boehringer Ingelheim Investigational Site
Hoorn, , Netherlands
1160.26.1359 Boehringer Ingelheim Investigational Site
Maastricht, , Netherlands
1160.26.1341 Boehringer Ingelheim Investigational Site
Meppel, , Netherlands
1160.26.1354 Boehringer Ingelheim Investigational Site
Rotterdam, , Netherlands
1160.26.1351 Boehringer Ingelheim Investigational Site
Sneek, , Netherlands
1160.26.1334 Boehringer Ingelheim Investigational Site
Spiijkenisse, , Netherlands
1160.26.1335 Boehringer Ingelheim Investigational Site
Terneuzen, , Netherlands
1160.26.1353 Boehringer Ingelheim Investigational Site
Tiel, , Netherlands
1160.26.1352 Boehringer Ingelheim Investigational Site
Tilburg, , Netherlands
1160.26.1350 Boehringer Ingelheim Investigational Site
Veldhoven, , Netherlands
1160.26.1342 Boehringer Ingelheim Investigational Site
Velp, , Netherlands
1160.26.1357 Boehringer Ingelheim Investigational Site
Venlo, , Netherlands
1160.26.1396 Boehringer Ingelheim Investigational Site
Gjøvik, , Norway
1160.26.1393 Boehringer Ingelheim Investigational Site
Moss, , Norway
1160.26.1395 Boehringer Ingelheim Investigational Site
Nordbyhagen, , Norway
1160.26.1391 Boehringer Ingelheim Investigational Site
Oslo, , Norway
1160.26.1392 Boehringer Ingelheim Investigational Site
Oslo, , Norway
1160.26.1397 Boehringer Ingelheim Investigational Site
Oslo, , Norway
1160.26.1394 Boehringer Ingelheim Investigational Site
Rud, , Norway
1160.26.1415 Hospital Alberto Sabogal
Bella Vista, , Peru
1160.26.1411 Clinica San Felipe
Jesús MarÃa, , Peru
1160.26.1412 ClÃnica Anglo Americana
San Isidro, , Peru
1160.26.1413 Hospital Cayetano Heredia
San MartÃn de Porres, , Peru
1160.26.1414 ClÃnica Vesalio
Urbanización Sto Tomas de San Borja, , Peru
1160.26.1421 Philippine General Hospital
Manila, , Philippines
1160.26.1422 Manila Doctors Hospital
Manila, , Philippines
1160.26.1424 The Medical City
Pasig, , Philippines
1160.26.1423 Philippine Heart Center
Quezon City, , Philippines
1160.26.1425 St Lukes Medical Center
Quezon City, , Philippines
1160.26.1436 Boehringer Ingelheim Investigational Site
Gdynia, , Poland
1160.26.1438 Boehringer Ingelheim Investigational Site
Gdynia, , Poland
1160.26.1437 Boehringer Ingelheim Investigational Site
Gdynia Redlowo, , Poland
1160.26.1435 Boehringer Ingelheim Investigational Site
Katowice, , Poland
1160.26.1439 Boehringer Ingelheim Investigational Site
Krakow, , Poland
1160.26.1440 Boehringer Ingelheim Investigational Site
Krakow, , Poland
1160.26.1433 Boehringer Ingelheim Investigational Site
Puławy, , Poland
1160.26.1431 Boehringer Ingelheim Investigational Site
Warsaw, , Poland
1160.26.1432 Boehringer Ingelheim Investigational Site
Warsaw, , Poland
1160.26.1434 Boehringer Ingelheim Investigational Site
Zabrze, , Poland
1160.26.1456 Boehringer Ingelheim Investigational Site
Amadora, , Portugal
1160.26.1451 Boehringer Ingelheim Investigational Site
Carnaxide, , Portugal
1160.26.1454 Boehringer Ingelheim Investigational Site
Coimbra, , Portugal
1160.26.1459 Boehringer Ingelheim Investigational Site
Coimbra, , Portugal
1160.26.1457 Boehringer Ingelheim Investigational Site
Covilha, , Portugal
1160.26.1453 Boehringer Ingelheim Investigational Site
Lisbon, , Portugal
1160.26.1458 Boehringer Ingelheim Investigational Site
Lisbon, , Portugal
1160.26.1455 Boehringer Ingelheim Investigational Site
Porto, , Portugal
1160.26.1452 Boehringer Ingelheim Investigational Site
Setúbal, , Portugal
1160.26.1471 Boehringer Ingelheim Investigational Site
Bucharest, , Romania
1160.26.1472 Boehringer Ingelheim Investigational Site
Bucharest, , Romania
1160.26.1478 Boehringer Ingelheim Investigational Site
Cluj-Napoca, , Romania
1160.26.1501 Boehringer Ingelheim Investigational Site
Moscow, , Russia
1160.26.1502 Boehringer Ingelheim Investigational Site
Moscow, , Russia
1160.26.1503 Boehringer Ingelheim Investigational Site
Moscow, , Russia
1160.26.1504 Boehringer Ingelheim Investigational Site
Moscow, , Russia
1160.26.1505 Boehringer Ingelheim Investigational Site
Moscow, , Russia
1160.26.1506 Boehringer Ingelheim Investigational Site
Moscow, , Russia
1160.26.1507 Boehringer Ingelheim Investigational Site
Moscow, , Russia
1160.26.1508 Boehringer Ingelheim Investigational Site
Moscow, , Russia
1160.26.1509 Boehringer Ingelheim Investigational Site
Moscow, , Russia
1160.26.1510 Boehringer Ingelheim Investigational Site
Moscow, , Russia
1160.26.1511 Boehringer Ingelheim Investigational Site
Moscow, , Russia
1160.26.1512 Boehringer Ingelheim Investigational Site
Saint Petersburg, , Russia
1160.26.1513 Boehringer Ingelheim Investigational Site
Saint Petersburg, , Russia
1160.26.1514 Boehringer Ingelheim Investigational Site
Saint Petersburg, , Russia
1160.26.1515 Boehringer Ingelheim Investigational Site
Saint Petersburg, , Russia
1160.26.1531 Boehringer Ingelheim Investigational Site
Singapore, , Singapore
1160.26.1532 Boehringer Ingelheim Investigational Site
Singapore, , Singapore
1160.26.1548 Boehringer Ingelheim Investigational Site
Banská Bystrica, , Slovakia
1160.26.1541 Boehringer Ingelheim Investigational Site
Bratislava, , Slovakia
1160.26.1542 Boehringer Ingelheim Investigational Site
Bratislava, , Slovakia
1160.26.1543 Boehringer Ingelheim Investigational Site
Bratislava, , Slovakia
1160.26.1544 Boehringer Ingelheim Investigational Site
Bratislava, , Slovakia
1160.26.1545 Boehringer Ingelheim Investigational Site
Bratislava, , Slovakia
1160.26.1546 Boehringer Ingelheim Investigational Site
Bratislava, , Slovakia
1160.26.1549 Boehringer Ingelheim Investigational Site
Košice, , Slovakia
1160.26.1550 Boehringer Ingelheim Investigational Site
Košice, , Slovakia
1160.26.1547 Boehringer Ingelheim Investigational Site
Žilina, , Slovakia
1160.26.1562 Boehringer Ingelheim Investigational Site
Bloemfontein, , South Africa
1160.26.1569 Boehringer Ingelheim Investigational Site
Boksburg, , South Africa
1160.26.1561 Boehringer Ingelheim Investigational Site
Cape Town, , South Africa
1160.26.1564 Boehringer Ingelheim Investigational Site
Johannesburg, , South Africa
1160.26.1567 Boehringer Ingelheim Investigational Site
Johannesburg, , South Africa
1160.26.1568 Boehringer Ingelheim Investigational Site
Johannesburg, , South Africa
1160.26.1566 Boehringer Ingelheim Investigational Site
Pretoria, , South Africa
1160.26.1563 Boehringer Ingelheim Investigational Site
Randburg, , South Africa
1160.26.1565 Boehringer Ingelheim Investigational Site
Somerset West, , South Africa
1160.26.1585 Boehringer Ingelheim Investigational Site
Busan, , South Korea
1160.26.1586 Boehringer Ingelheim Investigational Site
Chungchungnam-Do, , South Korea
1160.26.1584 Boehringer Ingelheim Investigational Site
Daegu, , South Korea
1160.26.1591 Boehringer Ingelheim Investigational Site
Daegu, , South Korea
1160.26.1590 Boehringer Ingelheim Investigational Site
Gwangju, , South Korea
1160.26.1581 Boehringer Ingelheim Investigational Site
Incheon, , South Korea
1160.26.1582 Boehringer Ingelheim Investigational Site
Seoul, , South Korea
1160.26.1583 Boehringer Ingelheim Investigational Site
Seoul, , South Korea
1160.26.1588 Boehringer Ingelheim Investigational Site
Seoul, , South Korea
1160.26.1589 Boehringer Ingelheim Investigational Site
Seoul, , South Korea
1160.26.1592 Boehringer Ingelheim Investigational Site
Seoul, , South Korea
1160.26.1593 Boehringer Ingelheim Investigational Site
Seoul, , South Korea
1160.26.1601 Boehringer Ingelheim Investigational Site
Barcelona, , Spain
1160.26.1606 Boehringer Ingelheim Investigational Site
Cadiz, , Spain
1160.26.1607 Boehringer Ingelheim Investigational Site
Fuenlabrada (Madrid), , Spain
1160.26.1604 Boehringer Ingelheim Investigational Site
Leganés, Madrid, , Spain
1160.26.1603 Boehringer Ingelheim Investigational Site
Madrid, , Spain
1160.26.1608 Boehringer Ingelheim Investigational Site
Madrid, , Spain
1160.26.1609 Boehringer Ingelheim Investigational Site
Madrid-San Lorenzo Del Escorial, , Spain
1160.26.1605 Boehringer Ingelheim Investigational Site
Móstoles (Madrid), , Spain
1160.26.1602 Boehringer Ingelheim Investigational Site
Sabadell, , Spain
1160.26.1633 Sahlgrenska Sjukhuset
Göteboerg, , Sweden
1160.26.1629 AVK-mott, Spec.M1, Länssjukhuset Ryhov
Jönköping, , Sweden
1160.26.1631 Universitetssjukhuset i Linköping
Linköping, , Sweden
1160.26.1627 Hjärtmott. ING 35, Malmö Universitetssjukhus MAS
Malmo, , Sweden
1160.26.1628 Rådhusg. 29, Lars Mörlids Läkarmottagning
Nässjö, , Sweden
1160.26.1625 Hjärtmott./Medicinkliniken, Vrinnevisjukhuset
Norrköping, , Sweden
1160.26.1623 Kardiologiska kliniken, Universitetssjukhuset
Örebro, , Sweden
1160.26.1626 Hjärtkärllaboratoriet, Danderyds Sjukhus AB
Stockholm, , Sweden
1160.26.1632 Capio S:t Görans Sjukhus
Stockholm, , Sweden
1160.26.1634 Södersjukhuset
Stockholm, , Sweden
1160.26.1624 Klin. forskningscentrum, Norrlands Universitetssjukhus
Umeå, , Sweden
1160.26.1621 Kardiologiska kliniken, Akademiska Sjukhuset
Uppsala, , Sweden
1160.26.1635 UCR/Uppsala
Uppsala, , Sweden
1160.26.1622 Hjärtmottagningen, Centrallasarettet
Västerås, , Sweden
1160.26.1652 Boehringer Ingelheim Investigational Site
Basel, , Switzerland
1160.26.1655 Boehringer Ingelheim Investigational Site
Bellinzona, , Switzerland
1160.26.1651 Boehringer Ingelheim Investigational Site
Bern, , Switzerland
1160.26.1654 Boehringer Ingelheim Investigational Site
Lugano, , Switzerland
1160.26.1680 Boehringer Ingelheim Investigational Site
Changhua County, , Taiwan
1160.26.1683 Boehringer Ingelheim Investigational Site
Hualien City, , Taiwan
1160.26.1682 Boehringer Ingelheim Investigational Site
Kaohsiung City, , Taiwan
1160.26.1679 China Medical University Hospital
Taichung, , Taiwan
1160.26.1681 Boehringer Ingelheim Investigational Site
Tainan City, , Taiwan
1160.26.1671 Boehringer Ingelheim Investigational Site
Taipei, , Taiwan
1160.26.1672 Boehringer Ingelheim Investigational Site
Taipei, , Taiwan
1160.26.1673 Boehringer Ingelheim Investigational Site
Taipei, , Taiwan
1160.26.1674 Boehringer Ingelheim Investigational Site
Taipei, , Taiwan
1160.26.1675 Boehringer Ingelheim Investigational Site
Taipei, , Taiwan
1160.26.1676 Boehringer Ingelheim Investigational Site
Taipei, , Taiwan
1160.26.1677 Boehringer Ingelheim Investigational Site
Taipei, , Taiwan
1160.26.1678 Boehringer Ingelheim Investigational Site
Taoyuan District, , Taiwan
1160.26.1701 Boehringer Ingelheim Investigational Site
Bangkok, , Thailand
1160.26.1702 Boehringer Ingelheim Investigational Site
Bangkok, , Thailand
1160.26.1703 Boehringer Ingelheim Investigational Site
Chiang Mai, , Thailand
1160.26.1704 Boehringer Ingelheim Investigational Site
Khon Kaen, , Thailand
1160.26.1705 Boehringer Ingelheim Investigational Site
Muang Nakhonratchasima, , Thailand
1160.26.1715 Boehringer Ingelheim Investigational Site
Adana, , Turkey (Türkiye)
1160.26.1711 Boehringer Ingelheim Investigational Site
Ankara, , Turkey (Türkiye)
1160.26.1713 Gazi Universitesi Tip Fakultesi Kardiyoloji Abd
Ankara, , Turkey (Türkiye)
1160.26.1714 Dokuz Eylul Universitesi Tip Fakultesi
Izmir, , Turkey (Türkiye)
1160.26.1727 Boehringer Ingelheim Investigational Site
Dnyepropetrovsk, , Ukraine
1160.26.1724 Boehringer Ingelheim Investigational Site
Kharkiv, , Ukraine
1160.26.1725 Boehringer Ingelheim Investigational Site
Kharkiv, , Ukraine
1160.26.1726 Boehringer Ingelheim Investigational Site
Kharkiv, , Ukraine
1160.26.1721 Boehringer Ingelheim Investigational Site
Kiev, , Ukraine
1160.26.1722 Boehringer Ingelheim Investigational Site
Kiev, , Ukraine
1160.26.1723 Boehringer Ingelheim Investigational Site
Kiev, , Ukraine
1160.26.1728 Boehringer Ingelheim Investigational Site
Kiev, , Ukraine
1160.26.1730 Boehringer Ingelheim Investigational Site
Kiev, , Ukraine
1160.26.1731 Boehringer Ingelheim Investigational Site
Kiev, , Ukraine
1160.26.1729 Boehringer Ingelheim Investigational Site
Lviv, , Ukraine
1160.26.1744 Boehringer Ingelheim Investigational Site
Birmingham, , United Kingdom
1160.26.1746 Boehringer Ingelheim Investigational Site
Chertsey, , United Kingdom
1160.26.1747 Boehringer Ingelheim Investigational Site
Glasgow, , United Kingdom
1160.26.1750 Boehringer Ingelheim Investigational Site
Harrow, , United Kingdom
1160.26.1753 Boehringer Ingelheim Investigational Site
Hull, , United Kingdom
1160.26.1755 Boehringer Ingelheim Investigational Site
Kirkcaldy, Fife, , United Kingdom
1160.26.1741 Boehringer Ingelheim Investigational Site
London, , United Kingdom
1160.26.1756 Boehringer Ingelheim Investigational Site
London, , United Kingdom
1160.26.1749 Boehringer Ingelheim Investigational Site
Londonderry, , United Kingdom
1160.26.1742 Boehringer Ingelheim Investigational Site
Newcastle upon Tyne, , United Kingdom
1160.26.1751 Boehringer Ingelheim Investigational Site
Newport, , United Kingdom
1160.26.1752 Boehringer Ingelheim Investigational Site
Northampton, , United Kingdom
1160.26.1745 Boehringer Ingelheim Investigational Site
Portadown, County Atrim, , United Kingdom
1160.26.1743 Boehringer Ingelheim Investigational Site
Romford, Essex, , United Kingdom
1160.26.1754 Boehringer Ingelheim Investigational Site
Stoke-on-Trent, , United Kingdom
1160.26.1748 Boehringer Ingelheim Investigational Site
York, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Hijazi Z, Lindback J, Oldgren J, Benz AP, Alexander JH, Connolly SJ, Eikelboom JW, Granger CB, Lopes RD, Siegbahn A, Wallentin L. Individual net clinical outcome with oral anticoagulation in atrial fibrillation using the ABC-AF risk scores. Am Heart J. 2023 Jul;261:55-63. doi: 10.1016/j.ahj.2023.03.012. Epub 2023 Mar 27.
Reinhardt SW, Desai NR, Tang Y, Jones PG, Ader J, Spertus JA. Personalizing the decision of dabigatran versus warfarin in atrial fibrillation: A secondary analysis of the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) trial. PLoS One. 2021 Aug 19;16(8):e0256338. doi: 10.1371/journal.pone.0256338. eCollection 2021.
Pol T, Hijazi Z, Lindback J, Oldgren J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Granger CB, Lopes RD, Yusuf S, Siegbahn A, Wallentin L. Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation. Cardiovasc Res. 2022 Jul 20;118(9):2112-2123. doi: 10.1093/cvr/cvab262.
Millenaar D, Schumacher H, Brueckmann M, Eikelboom JW, Ezekowitz M, Slawik J, Ewen S, Ukena C, Wallentin L, Connolly S, Yusuf S, Bohm M. Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial). Am J Cardiol. 2021 Jun 15;149:27-35. doi: 10.1016/j.amjcard.2021.03.024. Epub 2021 Mar 20.
Pol T, Hijazi Z, Lindback J, Alexander JH, Bahit MC, De Caterina R, Eikelboom JW, Ezekowitz MD, Gersh BJ, Granger CB, Hylek EM, Lopes R, Siegbahn A, Wallentin L. Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas. Open Heart. 2021 Mar;8(1):e001471. doi: 10.1136/openhrt-2020-001471.
Hijazi Z, Wallentin L, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Granger CB, Lopes RD, Pol T, Yusuf S, Oldgren J, Siegbahn A. Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation. J Am Heart Assoc. 2020 Dec 15;9(24):e018984. doi: 10.1161/JAHA.120.018984. Epub 2020 Dec 9.
Wallentin L, Lindback J, Eriksson N, Hijazi Z, Eikelboom JW, Ezekowitz MD, Granger CB, Lopes RD, Yusuf S, Oldgren J, Siegbahn A. Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation. Eur Heart J. 2020 Nov 1;41(41):4037-4046. doi: 10.1093/eurheartj/ehaa697.
Bohm M, Brueckmann M, Eikelboom JW, Ezekowitz M, Frassdorf M, Hijazi Z, Hohnloser SH, Mahfoud F, Schmieder RE, Schumacher H, Wallentin L, Yusuf S. Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial. Eur Heart J. 2020 Aug 7;41(30):2848-2859. doi: 10.1093/eurheartj/ehaa247.
Stam-Slob MC, Connolly SJ, van der Graaf Y, van der Leeuw J, Dorresteijn JAN, Eikelboom JW, Peters RJG, Alings M, Visseren FLJ. Individual Treatment Effect Estimation of 2 Doses of Dabigatran on Stroke and Major Bleeding in Atrial Fibrillation. Circulation. 2019 Jun 18;139(25):2846-2856. doi: 10.1161/CIRCULATIONAHA.118.035266. Epub 2019 May 3.
Hijazi Z, Verdecchia P, Oldgren J, Andersson U, Reboldi G, Di Pasquale G, Mazzotta G, Angeli F, Eikelboom JW, Ezekowitz MD, Connolly SJ, Yusuf S, Wallentin L. Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE - LY Trial. J Am Heart Assoc. 2019 Jan 22;8(2):e010107. doi: 10.1161/JAHA.118.010107.
Kent AP, Brueckmann M, Fraessdorf M, Connolly SJ, Yusuf S, Eikelboom JW, Oldgren J, Reilly PA, Wallentin L, Ezekowitz MD. Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation. J Am Coll Cardiol. 2018 Jul 17;72(3):255-267. doi: 10.1016/j.jacc.2018.04.063. Epub 2018 Jul 9.
Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, Reilly PA, Yusuf S, Wallentin L. Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis. Am Heart J. 2018 Apr;198:169-177. doi: 10.1016/j.ahj.2017.10.015. Epub 2018 Jan 5. No abstract available.
Hijazi Z, Oldgren J, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Held C, Hylek EM, Lopes RD, Yusuf S, Granger CB, Siegbahn A, Wallentin L; ARISTOTLE and RE-LY Investigators. A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score. Eur Heart J. 2018 Feb 7;39(6):477-485. doi: 10.1093/eurheartj/ehx584.
Verdecchia P, Reboldi G, Angeli F, Mazzotta G, Lip GYH, Brueckmann M, Kleine E, Wallentin L, Ezekowitz MD, Yusuf S, Connolly SJ, Di Pasquale G. Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation- the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study. Europace. 2018 Feb 1;20(2):253-262. doi: 10.1093/europace/eux022.
Lauw MN, Eikelboom JW, Coppens M, Wallentin L, Yusuf S, Ezekowitz M, Oldgren J, Nakamya J, Wang J, Connolly SJ. Effects of dabigatran according to age in atrial fibrillation. Heart. 2017 Jul;103(13):1015-1023. doi: 10.1136/heartjnl-2016-310358. Epub 2017 Feb 17.
Oldgren J, Hijazi Z, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Granger CB, Hylek EM, Lopes RD, Siegbahn A, Yusuf S, Wallentin L; RE-LY and ARISTOTLE Investigators. Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. Circulation. 2016 Nov 29;134(22):1697-1707. doi: 10.1161/CIRCULATIONAHA.116.022802. Epub 2016 Aug 28.
Ezekowitz MD, Nagarakanti R, Noack H, Brueckmann M, Litherland C, Jacobs M, Clemens A, Reilly PA, Connolly SJ, Yusuf S, Wallentin L. Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy). Circulation. 2016 Aug 23;134(8):589-98. doi: 10.1161/CIRCULATIONAHA.115.020950. Epub 2016 Aug 5.
Hijazi Z, Oldgren J, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Held C, Hylek EM, Lopes RD, Siegbahn A, Yusuf S, Granger CB, Wallentin L; ARISTOTLE and RE-LY Investigators. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet. 2016 Jun 4;387(10035):2302-2311. doi: 10.1016/S0140-6736(16)00741-8. Epub 2016 Apr 4.
Siegbahn A, Oldgren J, Andersson U, Ezekowitz MD, Reilly PA, Connolly SJ, Yusuf S, Wallentin L, Eikelboom JW. D-dimer and factor VIIa in atrial fibrillation - prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudy. Thromb Haemost. 2016 May 2;115(5):921-30. doi: 10.1160/TH15-07-0529. Epub 2016 Jan 28.
Aulin J, Siegbahn A, Hijazi Z, Ezekowitz MD, Andersson U, Connolly SJ, Huber K, Reilly PA, Wallentin L, Oldgren J. Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation. Am Heart J. 2015 Dec;170(6):1151-60. doi: 10.1016/j.ahj.2015.09.018. Epub 2015 Oct 3.
Brambatti M, Darius H, Oldgren J, Clemens A, Noack HH, Brueckmann M, Yusuf S, Wallentin L, Ezekowitz MD, Connolly SJ, Healey JS. Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial. Int J Cardiol. 2015 Oct 1;196:127-31. doi: 10.1016/j.ijcard.2015.05.141. Epub 2015 May 28.
Bohm M, Ezekowitz MD, Connolly SJ, Eikelboom JW, Hohnloser SH, Reilly PA, Schumacher H, Brueckmann M, Schirmer SH, Kratz MT, Yusuf S, Diener HC, Hijazi Z, Wallentin L. Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial. J Am Coll Cardiol. 2015 Jun 16;65(23):2481-93. doi: 10.1016/j.jacc.2015.03.577.
Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD, Hohnloser SH, Reilly PA, Siegbahn A, Yusuf S, Wallentin L. Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy. Heart. 2014 Aug;100(15):1193-200. doi: 10.1136/heartjnl-2013-304872. Epub 2014 May 2.
Verdecchia P, Reboldi G, Di Pasquale G, Mazzotta G, Ambrosio G, Yang S, Pogue J, Wallentin L, Ezekowitz MD, Connolly SJ, Yusuf S; RE-LY Study Investigators. Prognostic usefulness of left ventricular hypertrophy by electrocardiography in patients with atrial fibrillation (from the Randomized Evaluation of Long-Term Anticoagulant Therapy Study). Am J Cardiol. 2014 Feb 15;113(4):669-75. doi: 10.1016/j.amjcard.2013.10.045. Epub 2013 Nov 23.
Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, Reilly PA, Siegbahn A, Yusuf S, Wallentin L. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation. 2014 Mar 4;129(9):961-70. doi: 10.1161/CIRCULATIONAHA.113.003628. Epub 2013 Dec 9.
Majeed A, Hwang HG, Connolly SJ, Eikelboom JW, Ezekowitz MD, Wallentin L, Brueckmann M, Fraessdorf M, Yusuf S, Schulman S. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation. 2013 Nov 19;128(21):2325-32. doi: 10.1161/CIRCULATIONAHA.113.002332. Epub 2013 Sep 30.
Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz MD, Nehmiz G, Wang S, Wallentin L; RE-LY Investigators. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 2014 Feb 4;63(4):321-8. doi: 10.1016/j.jacc.2013.07.104. Epub 2013 Sep 27.
Marijon E, Le Heuzey JY, Connolly S, Yang S, Pogue J, Brueckmann M, Eikelboom J, Themeles E, Ezekowitz M, Wallentin L, Yusuf S; RE-LY Investigators. Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study. Circulation. 2013 Nov 12;128(20):2192-201. doi: 10.1161/CIRCULATIONAHA.112.000491. Epub 2013 Sep 9.
Eikelboom JW, Connolly SJ, Hart RG, Wallentin L, Reilly P, Oldgren J, Yang S, Yusuf S. Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation. J Am Coll Cardiol. 2013 Sep 3;62(10):900-8. doi: 10.1016/j.jacc.2013.05.042. Epub 2013 Jun 13.
Hori M, Connolly SJ, Zhu J, Liu LS, Lau CP, Pais P, Xavier D, Kim SS, Omar R, Dans AL, Tan RS, Chen JH, Tanomsup S, Watanabe M, Koyanagi M, Ezekowitz MD, Reilly PA, Wallentin L, Yusuf S; RE-LY Investigators. Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke. 2013 Jul;44(7):1891-6. doi: 10.1161/STROKEAHA.113.000990. Epub 2013 Jun 6.
Pare G, Eriksson N, Lehr T, Connolly S, Eikelboom J, Ezekowitz MD, Axelsson T, Haertter S, Oldgren J, Reilly P, Siegbahn A, Syvanen AC, Wadelius C, Wadelius M, Zimdahl-Gelling H, Yusuf S, Wallentin L. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation. 2013 Apr 2;127(13):1404-12. doi: 10.1161/CIRCULATIONAHA.112.001233. Epub 2013 Mar 6.
Dans AL, Connolly SJ, Wallentin L, Yang S, Nakamya J, Brueckmann M, Ezekowitz M, Oldgren J, Eikelboom JW, Reilly PA, Yusuf S. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation. 2013 Feb 5;127(5):634-40. doi: 10.1161/CIRCULATIONAHA.112.115386. Epub 2012 Dec 27.
Bytzer P, Connolly SJ, Yang S, Ezekowitz M, Formella S, Reilly PA, Aisenberg J. Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. Clin Gastroenterol Hepatol. 2013 Mar;11(3):246-52.e1-5. doi: 10.1016/j.cgh.2012.10.021. Epub 2012 Oct 24.
Van Spall HG, Wallentin L, Yusuf S, Eikelboom JW, Nieuwlaat R, Yang S, Kabali C, Reilly PA, Ezekowitz MD, Connolly SJ. Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation. 2012 Nov 6;126(19):2309-16. doi: 10.1161/CIRCULATIONAHA.112.101808. Epub 2012 Oct 1.
Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, Themeles E, Heidbuchel H, Avezum A, Reilly P, Connolly SJ, Yusuf S, Ezekowitz M; RE-LY Investigators. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation. 2012 Jul 17;126(3):343-8. doi: 10.1161/CIRCULATIONAHA.111.090464. Epub 2012 Jun 14.
Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD, Hohnloser SH, Reilly PA, Vinereanu D, Siegbahn A, Yusuf S, Wallentin L. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. Circulation. 2012 Apr 3;125(13):1605-16. doi: 10.1161/CIRCULATIONAHA.111.038729. Epub 2012 Feb 28.
Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P, Eikelboom J, Brueckmann M, Yusuf S, Connolly SJ. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation. 2012 Feb 7;125(5):669-76. doi: 10.1161/CIRCULATIONAHA.111.055970. Epub 2012 Jan 3.
Oldgren J, Alings M, Darius H, Diener HC, Eikelboom J, Ezekowitz MD, Kamensky G, Reilly PA, Yang S, Yusuf S, Wallentin L, Connolly SJ; RE-LY Investigators. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med. 2011 Nov 15;155(10):660-7, W204. doi: 10.7326/0003-4819-155-10-201111150-00004.
Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011 May 31;123(21):2363-72. doi: 10.1161/CIRCULATIONAHA.110.004747. Epub 2011 May 16.
Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH, Flaker G, Brugada J, Kamensky G, Parekh A, Reilly PA, Yusuf S, Connolly SJ. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011 Jan 18;123(2):131-6. doi: 10.1161/CIRCULATIONAHA.110.977546. Epub 2011 Jan 3.
Ezekowitz MD, Wallentin L, Connolly SJ, Parekh A, Chernick MR, Pogue J, Aikens TH, Yang S, Reilly PA, Lip GY, Yusuf S; RE-LY Steering Committee and Investigators. Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation. 2010 Nov 30;122(22):2246-53. doi: 10.1161/CIRCULATIONAHA.110.973735.
Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S, Xavier D, Di Pasquale G, Yusuf S; RE-LY study group. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol. 2010 Dec;9(12):1157-1163. doi: 10.1016/S1474-4422(10)70274-X. Epub 2010 Nov 6.
Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, Pais P, Dans A, Eikelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ; RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010 Sep 18;376(9745):975-83. doi: 10.1016/S0140-6736(10)61194-4.
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139-51. doi: 10.1056/NEJMoa0905561. Epub 2009 Aug 30.
Ezekowitz MD, Connolly S, Parekh A, Reilly PA, Varrone J, Wang S, Oldgren J, Themeles E, Wallentin L, Yusuf S. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J. 2009 May;157(5):805-10, 810.e1-2. doi: 10.1016/j.ahj.2009.02.005.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2005-003894-26
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
1160.26
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.